{"title": "PDF", "author": "PDF", "url": "http://degette.house.gov/sites/evo-subsites/degette-evo.house.gov/files/CURES%202.0%20Text.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "117 THCONGRESS 1STSESSION H. R. ll To continue the acceleration of the discovery, development, and delivery of 21st century cures, and for other purposes. IN THE HOUSE OF REPRESENTATIVES Ms. D EGETTE introduced the following bill; which was referred to the Committee on llllllllllllll A BILL To continue the acceleration of the discovery, development, and delivery of 21st century cures, and for other purposes. Be it enacted by the Senate and House of Representa- 1 tives of the United States of America in Congress assembled, 2 SECTION 1. SHORT TITLE. 3 This Act may be cited as the ''Cures 2.0 Act''. 4 SEC. 2. TABLE OF CONTENTS. 5 The table of contents of this Act is as follows: 6 Sec. 1. Short title. Sec. 2. Table of contents. TITLE I\u2014PUBLIC HEALTH Sec. 101. Further understanding the implications of long COVID. VerDate Nov 24 2008 15:17 National strategy to prevent and respond to pandemics. Sec. 103. Pandemic preparedness rare disease support program. Sec. 104. Vaccine and immunization programs. Sec. 105. Developing antimicrobial innovations. TITLE II\u2014PATIENTS AND CAREGIVERS Sec. 201. Educational programs and training for caregivers. Sec. 202. Increasing health literacy to promote better outcomes for patients. Sec. 203. Increasing diversity in clinical trials. Sec. 204. Patient experience data. Sec. 205. Ensuring coverage for clinical trials under existing standard of care. TITLE III\u2014FOOD AND DRUG ADMINISTRATION Sec. 301. Report on collaboration and alignment in regulating digital health technologies. Sec. 302. Grants for novel trial designs and other innovations in drug develop- ment. Sec. 303. FDA cell and gene therapy. Sec. 304. Increasing use of real world evidence. Sec. 305. Improving FDA-CMS communication regarding transformative new therapies. Sec. 306. Establishment of additional Intercenter Institutes at the Food and Drug Administration. Sec. 307. Accelerating timeline for breakthrough and RMAT designations. Sec. 308. Guidance regarding development and submission of chemistry, manu- facturing, and controls information for expedited approval. Sec. 309. Post-approval study requirements for accelerated approval. Sec. 310. Recommendations to decentralize clinical trials. TITLE IV\u2014CENTERS FOR MEDICARE & MEDICAID SERVICES Sec. 401. GAO study and report. Sec. 402. Strategies to increase access to telehealth under Medicaid and Chil- dren's Health Insurance Program. Sec. 403. Extending Medicare telehealth flexibilities. Sec. 404. Coverage and payment for breakthrough devices under the medicare program. Sec. 405. Secretary of Health and Human Services report on coverage for inno- vative technologies. Sec. 406. Secretary of Health and Human Services report on CMS computer systems. Sec. 407. Precision Medicine Answers for Kids Today. Sec. 408. Medicare coverage for consultations. Sec. 409. Prohibiting the use of geographic tracking features and biometrics within Medicaid electronic visit verification systems. Sec. 410. Generally accepted standard for electronic prescribing. Sec. 411. Meaningful access to Federal health plan claims data. TITLE V\u2014RESEARCH Sec. 501. Advanced Research Projects Agency for Health. Sec. 502. Research investment to spark the economy. Sec. 503. Research Policy Board reauthorization. VerDate Nov 24 2008 HEALTH 1 SEC. 101. FURTHER UNDERSTANDING THE IMPLICATIONS 2 OF LONG COVID. 3 (a) S OURCES OF COVERAGE SURVEY .\u2014The Sec- 4 retary of Health and Human Services shall\u2014 5 (1) conduct a large national survey of patients 6 who self-identify as having long COVID to assess 7 sources of health coverage, long-term care coverage, 8 and disability coverage for long COVID and related 9 symptoms; and 10 (2) not later than 6 months after the date of 11 enactment of this Act, complete such survey and 12 submit a report on the results of such survey to the 13 Committees on Energy and Commerce, Ways and 14 Means, and Education and Labor of the House of 15 Representatives and the Committees on Health, 16 Education, Labor, and Pensions and Finance of the 17 Senate. 18 (b) L EARNING COLLABORATIVE .\u2014 19 (1) N ATIONAL MEETINGS .\u2014The Secretary of 20 Health and Human Services shall\u2014 21 (A) convene a series of not less than four 22 national meetings, that may be virtual, to serve 23 as the basis of an ongoing long COVID learning 24 collaborative with individuals and organizations 25 VerDate Nov 24 2008 sectors of the health care com- 1 munity; and 2 (B) invite to participate in such meetings 3 individuals who represent the views of health 4 plan representatives, health care providers (in- 5 cluding hospitals, physicians, and nurses), med- 6 ical and scientific researchers, patient and con- 7 sumer advocates, data scientists, health care 8 service providers, providers of workers com- 9 pensation, employers, and developers of diag- 10 nostic and therapeutic products, including clin- 11 ical laboratories. 12 (2) T ERMINATION OF MEETINGS .\u2014The Sec- 13 retary shall continue to convene national meetings 14 under paragraph (1) for\u2014 15 (A) not less than 2 years after the date of 16 the enactment of this Act; and 17 (B) each fiscal year thereafter, unless the 18 Secretary determines that the public health and 19 medical knowledge with respect to long COVID 20 has sufficiently advanced to ensure widespread 21 understanding of the characteristics of long 22 COVID, including\u2014 23 VerDate Nov 24 2008 etiology, progression, similarity 1 to other conditions, and duration of long 2 COVID; and 3 (ii) conditions that interact with long 4 COVID. 5 (c) L ONG COVID S CIENTIFIC RESEARCH FOR CHIL- 6 DREN .\u2014 7 (1) I N GENERAL .\u2014Beginning not later than 8 180 days after the date of the enactment of this Act, 9 the Director of the National Institutes of Health 10 shall award grants to hospitals for children, pedi- 11 atric researchers, academic medical centers, and 12 other appropriate organizations to research the long- 13 term effects and treatment of COVID-19 in chil- 14 dren, including long COVID. 15 (2) A UTHORIZATION OF APPROPRIATIONS .\u2014Of 16 the amounts made available for research and clinical 17 trials related to long-term studies of COVID-19 18 under the heading ''National Institutes of Health \u2014 19 Office of the Director'' of title III of the Consoli- 20 dated Appropriations Act, 2021 (Public Law 116- 21 260), there are authorized to be appropriated such 22 sums as may be necessary to carry out this sub- 23 section. 24 (d) S TUDY ON DISPARITIES IN LONG COVID.\u2014 25 VerDate Nov 24 N GENERAL .\u2014Not later than 90 days after 1 the date of the enactment of this Act, the Secretary 2 of Health and Human Services shall seek to enter 3 into an arrangement with the National Academy of 4 Medicine under which the Academy conducts a study 5 to evaluate disparities in racial and ethnic minority 6 groups with respect to diagnosis of, severity of 7 symptoms, access to care, and treatment for long 8 COVID. 9 (2) C ONTENT .\u2014The study under paragraph (1) 10 shall\u2014 11 (A) with respect to individuals who are 12 Black, Hispanic, American Indian, Alaska Na- 13 tive, or who belong to other racial and ethnic 14 populations\u2014 15 (i) evaluate the prevalence of long 16 COVID; 17 (ii) evaluate the rates of hospitaliza- 18 tion and death from COVID-19; and 19 (iii) evaluate and identify factors that 20 increase the risk of severity of long 21 COVID; and 22 (B) include recommendations to identify 23 and address the disparities described in para- 24 VerDate Nov 24 2008 including the causes of such dispari- 1 ties. 2 (3) A UTHORIZATION OF APPROPRIATIONS .\u2014 3 There is authorized to be appropriated to carry out 4 this subsection $5,000,000 for fiscal year 2022, to 5 remain available until expended. 6 (e) E DUCATION AND DISSEMINATION OF INFORMA - 7 TION WITH RESPECT TO LONG-TERM SYMPTOMS OF 8 COVID-19.\u2014 9 (1) L ONG COVID PUBLIC EDUCATION PRO - 10 GRAM .\u2014The Secretary of Health and Human Serv- 11 ices, acting through the Director of the Centers for 12 Disease Control and Prevention, shall develop and 13 disseminate to the public information regarding long 14 COVID, including information on\u2014 15 (A) the awareness, incidence, and common 16 symptoms of long COVID; and 17 (B) the availability, as medically appro- 18 priate, of treatment options for long COVID. 19 (2) L ONG COVID PROVIDER EDUCATION PRO - 20 GRAM .\u2014The Secretary of Health and Human Serv- 21 ices, acting through the Director of the Centers for 22 Disease Control and Prevention, shall in consulta- 23 tion with communities of individuals diagnosed with 24 long COVID, develop and disseminate to health care 25 VerDate Nov 24 2008 15:17 on long COVID for the pur- 1 pose of ensuring that such providers remain in- 2 formed about current information on long COVID. 3 (3) A RRANGEMENT AUTHORITY .\u2014The Sec- 4 retary Health and Human Services may disseminate 5 information under paragraphs (1) and (2) directly or 6 through arrangements with intra-agency initiatives, 7 nonprofit organizations, consumer groups, institu- 8 tions of higher learning (as defined in section 101 9 of the Higher Education Act of 1965 (20 U.S.C. 10 1001)), or Federal, State, or local public private 11 partnerships. 12 (4) A UTHORIZATION OF APPROPRIATIONS .\u2014 13 There is authorized to be appropriated to carry out 14 this section $30,000,000 for fiscal year 2022, which 15 shall remain available until expended. 16 SEC. 102. NATIONAL STRATEGY TO PREVENT AND RESPOND 17 TO PANDEMICS. 18 (a) I NGENERAL .\u2014Not later than 90 days after the 19 date of enactment of this Act, the President, acting 20 through the Secretary of Health and Human Services, 21 shall\u2014 22 (1) develop and implement a national strategy 23 to prevent and respond to pandemics and other pub- 24 lic health emergencies for which a declaration is 25 VerDate Nov 24 2008 15:17 under section 319 of the Public Health Service 1 Act (42 U.S.C. 247d); and 2 (2) base such strategy on lessons learned, and 3 best practices developed, as a result of the COVID- 4 19 pandemic. 5 (b) C ONTENTS .\u2014The national strategy under sub- 6 section (a) shall at a minimum address each of the fol-7 lowing: 8 (1) Strategies for testing (including point-of- 9 care testing and testing at nonmedical sites) to fos- 10 ter expedient results and personalized medical re- 11 sponses for patients and communities, including for 12 medically underserved populations. 13 (2) Methods of data sharing to use testing to 14 inform surveillance and other pandemic monitoring 15 and response efforts. 16 (3) Strategies to enable Americans to continue 17 to work, or return to work, or continue to remain in, 18 or return to, in-person school and childcare settings 19 safely. 20 (4) Modernizing and expanding domestic drug 21 manufacturing, including through the use of contin- 22 uous manufacturing. 23 (5) Developing and administering vaccines, 24 therapeutics, and other medical supplies, including 25 VerDate Nov 24 2008 15:17 children, racial and ethnic minorities, and people 1 with disabilities. 2 SEC. 103. PANDEMIC PREPAREDNESS RARE DISEASE SUP-3 PORT PROGRAM. 4 Subtitle B of title XXVIII of the Public Health Serv- 5 ice Act (42 U.S.C. 300hh-10 et seq.) is amended by in-6 serting after 2815 of such Act the following: 7 ''SEC. 2816. PANDEMIC PREPAREDNESS PLAN. 8 ''(a) I NGENERAL .\u2014The Secretary, acting through 9 the Administrator of the Health Resources and Services 10 Administration and in collaboration with the Director of 11 the Centers for Disease Control and Prevention, shall 12 award grants to eligible organizations to develop a pan-13 demic preparedness plan regarding\u2014 14 ''(1) the challenges faced by patients and the 15 family caregivers of such patients served by the re- 16 spective eligible organizations during the COVID-19 17 pandemic; 18 ''(2) potential challenges for the respective eligi- 19 ble organizations during future pandemics and other 20 public health emergencies; 21 ''(3) how the respective eligible organizations 22 plan to overcome the challenges described in para- 23 graphs (1) and (2), including how the respective or- 24 ganizations plan to support patients, their families, 25 VerDate Nov 24 2008 15:17 to overcome such chal- 1 lenges; and 2 ''(4) efforts to partner with local, State, and 3 Federal governments to promote a coordinated re- 4 sponse to future pandemics and other public health 5 emergencies. 6 ''(b) P RIORITY .\u2014In awarding grants under this sec- 7 tion, the Secretary shall give priority to eligible organiza-8 tions that are rare disease or condition organizations. 9 ''(c) D EFINITIONS .\u2014In this section: 10 ''(1) The organization' means an 11 organization that\u2014 12 ''(A) is described in section 501(c) of the 13 Internal Revenue Code of 1986 and exempt 14 from tax under section 501(a) of such Code; 15 and 16 ''(B) provides support and other resources 17 to patients and their families for accessing and 18 paying for medical care. 19 ''(2) The term 'public health emergency' means 20 a public health emergency declared under section 21 319. 22 ''(3) The term 'rare disease or condition' has 23 the meaning given to such term in section 526(a) of 24 the Federal Food, Drug, and Cosmetic Act. 25 VerDate Nov 24 2008 15:17 APPROPRIATIONS .\u2014There 1 is authorized to be appropriated to carry out this section 2 $25,000,000 for each of fiscal years 2022 through 2024.''. 3 SEC. 104. VACCINE AND IMMUNIZATION PROGRAMS. 4 (a) A DDITIONAL FUNDING FOR VACCINE AWARE - 5 NESS .\u2014There are authorized to be appropriated to the 6 Centers for Disease Control and Prevention $25,000,000 7 for each of fiscal years 2022 through 2024 for the purpose 8 of carrying out an awareness campaign to educate the 9 public with respect to the safety and importance of vac-10 cines. The amounts authorized by the preceding sentence 11 are in addition to amounts otherwise available for such 12 purpose. 13 (b) S TRENGTHENING THE IMMUNIZATION INFORMA - 14 TION SYSTEM .\u2014There are authorized to be appropriated 15 to the Centers for Disease Control and Prevention 16 $25,000,000 for each of fiscal years 2022 through 2024 17 for the purpose of strengthening immunization informa-18 tion systems. The amounts authorized by the preceding 19 sentence are in addition to amounts otherwise available 20 for such purpose. 21 SEC. 105. DEVELOPING ANTIMICROBIAL INNOVATIONS. 22 Title III of the Public Health Service Act (42 U.S.C. 23 241 et seq.) is amended by adding at the end the fol-24 lowing: 25 VerDate Nov 24 ''(a) I NGENERAL .\u2014Not later than 60 days after the 5 date of enactment of this part, the Secretary shall estab-6 lish a Committee on Critical Need Antimicrobials and ap-7 point members to the Committee. 8 ''(b) M EMBERS .\u2014 9 ''(1) I N GENERAL .\u2014The Committee shall con- 10 sist of at least one representative from each of the 11 National Institute of Allergy and Infectious Dis- 12 eases, the Centers for Disease Control and Preven- 13 tion, the Biomedical Advanced Research and Devel- 14 opment Authority, the Food and Drug Administra- 15 tion, the Centers for Medicare & Medicaid Services, 16 the Veterans Health Administration, and the De- 17 partment of Defense. 18 ''(2) C HAIR .\u2014The Secretary shall appoint one 19 of the members of the Committee to serve as the 20 Chair of the Committee. 21 ''(c) D UTIES .\u2014Not later than 1 year after the ap- 22 pointment of all initial members of the Committee, the 23 Secretary, in collaboration with the Committee, and in 24 consultation with the Critical Need Antimicrobials Advi-25 VerDate Nov 24 shall do the 1 following: 2 ''(1) Develop a list of infections for which new 3 antimicrobial drug development is needed, taking 4 into account organisms, sites of infection, and type 5 of infections for which there is an unmet medical 6 need, findings from the most recent report entitled 7 'Antibiotic Resistance Threats in the United States' 8 issued by the Centers for Disease Control and Pre- 9 vention, or an anticipated unmet medical need, in- 10 cluding a potential global health security threat. For 11 the list developed under this paragraph, the Sec- 12 retary, in collaboration with the Committee, may use 13 the infection list in such most recent report for up 14 to 3 years following the date of enactment of this 15 part and subsequently update the list under this 16 paragraph in accordance with subsection (e). 17 ''(2) Develop regulations, in accordance with 18 subsection (d), outlining favored characteristics of 19 critical need antimicrobial drugs, that are evidence 20 based, clinically focused, and designed to treat the 21 infections described in paragraph (1), and estab- 22 lishing criteria for how each such characteristic will 23 adjust the monetary value of a subscription contract 24 awarded under subsection (f) or section 399QQ. The 25 VerDate Nov 24 characteristics shall be weighed for purposes 1 of such monetary value such that meeting certain 2 characteristics, or meeting more than one such char- 3 acteristic, increases the monetary value. Such fa- 4 vored characteristics of an antimicrobial drug shall 5 include\u2014 6 ''(A) treating infections on the list under 7 paragraph (1); 8 ''(B) improving clinical outcomes for pa- 9 multi-drug-resistant infections; 10 ''(C) being a first-approved antimicrobial 11 drug that has the potential to address unmet 12 medical needs for the treatment of a serious or 13 life-threatening infection, and, to a lesser ex- 14 tent, second and third drugs that treat such in- 15 fections; 16 ''(D) route of administration, especially 17 through oral administration; 18 ''(E)(i) containing no active moiety (as de- 19 fined by the Secretary in section 314.3 of title 20 21, Code of Federal Regulations (or any suc- 21 cessor regulations)) that has been approved in 22 any other application under section 505(b) of 23 the Federal Food, Drug, and Cosmetic Act or 24 intending to be the subject of a new original 25 VerDate Nov 24 2008 15:17 section 1 351(a); 2 ''(ii) being a member of a new class of 3 drugs with a novel target and novel mode of ac- 4 tion that are distinctly different from the target 5 or mode of any antimicrobial drug approved 6 under section 505 of such Act or licensed under 7 section 351, including reduced toxicity; 8 ''(iii) not being affected by cross-resistance 9 to any antimicrobial drug approved under such 10 section 505 or licensed under such section 351; 11 ''(F) addressing a multi-drug resistant in- 12 fection through a novel chemical scaffold or 13 mechanism of action; 14 ''(G) having received a transitional sub- 15 scription contract under subsection (f); and 16 ''(H) any other characteristic the Sec- 17 retary, in collaboration with the Committee, de- 18 termines necessary. 19 ''(d) R EGULATIONS .\u2014 20 ''(1) I N GENERAL .\u2014Not later than 1 year after 21 the appointment of the initial members of the Com- 22 mittee, the Secretary shall issue proposed regula- 23 tions which shall include\u2014 24 process by which the sponsors can 1 apply for an antimicrobial drug to become a 2 critical need antimicrobial drug under section 3 399PP; 4 ''(B) how subscription contracts under 5 such section shall be established and paid; 6 ''(C) the favored characteristics under sub- 7 section (c)(2), how such characteristics will be 8 weighed, and the minimum number and kind of 9 favored characteristics needed for an anti- 10 microbial drug to be designated a critical need 11 antimicrobial drug; and 12 ''(D) other elements of the subscription 13 contract process, in accordance with this part. 14 ''(2) D EVELOPMENT OF FINAL REGULA - 15 TIONS .\u2014Before finalizing the regulations under 16 paragraph (1), the Secretary shall solicit public com- 17 ment and hold public meetings for the period begin- 18 ning on the date on which the proposed regulations 19 are issued and ending on the date that is 120 days 20 after such date of issuance. The Secretary shall fi- 21 nalize and publish such regulations not later than 22 120 days after the close of such period of public 23 comment and meetings. 24 VerDate Nov 24 2008 15:17 OFFICE .\u2014Not 1 later than 6 months after the date of enactment of 2 this part, the Secretary shall propose an agency or 3 office in the Department of Health and Human 4 Services to manage the establishment and payment 5 of subscription contracts awarded under section 6 399QQ, including eligibility, requirements, and con- 7 tract amounts. The Secretary shall solicit public 8 comment and finalize the agency or office no later 9 than 45 days following the proposed agency or of- 10 fice. Such agency or office shall be referred to as the 11 'Subscription Contract Office'. 12 ''(e) L IST OF INFECTIONS .\u2014The Secretary, in col- 13 laboration with the Committee, shall update the list of in-14 fections under subsection (c)(1) at least every 2 years. 15 ''(f) T RANSITIONAL SUBSCRIPTION CONTRACTS .\u2014 16 ''(1) I N GENERAL .\u2014Not earlier than 30 days 17 after the date of enactment of this part and ending 18 on the date that the Secretary finalizes the subscrip- 19 tion contract regulations under subsection (d), the 20 Secretary may use up to $1,000,000,000 of the 21 amount appropriated under section 399SS(a) to en- 22 gage in transitional subscription contracts of up to 23 3 years in length with antimicrobial developers, as 24 determined by the Secretary, that have developed 25 VerDate Nov 24 2008 15:17 treating infections listed in the 1 most recent report entitled 'Antibiotic Resistance 2 Threats in the United States' issued by the Centers 3 for Disease Control and Prevention, and may include 4 antimicrobial drugs that are qualified infectious dis- 5 ease products (as defined in section 505E(g) of the 6 Federal Food, Drug, and Cosmetic Act), innovative 7 biological products, or innovative drugs that achieve 8 a clinical outcome through immunomodulation. Such 9 a contract may authorize the contractor to use funds 10 made available under the contract for completion of 11 postmarketing clinical studies, manufacturing, and 12 other preclinical and clinical efforts. 13 ''(2) R EQUIREMENTS .\u2014 14 ''(A) I N GENERAL .\u2014The Secretary, 15 through the office described in paragraph (4), 16 may enter into a contract under paragraph 17 (1)\u2014 18 ''(i) if the Secretary determines that 19 the antimicrobial drug is intended to treat 20 an infection for which there is an unmet 21 clinical need, an anticipated clinical need, 22 or drug resistance; 23 ''(ii) subject to terms including\u2014 24 the Secretary shall 1 cease any payment installments under 2 a transitional subscription contract if 3 the sponsor does not\u2014 4 ''(aa) ensure commercial and 5 Federal availability of the anti- 6 microbial drug within 30 days of 7 receiving first payment under the 8 contract; 9 ''(bb) identify, track, and 10 publicly report drug resistance 11 data and trends using available 12 data related to the antimicrobial 13 drug; 14 ''(cc) develop and implement 15 education and communications 16 strategies, including communica- 17 tions for individuals with limited 18 English proficiency and individ- 19 uals with disabilities, for health 20 care professionals and patients 21 about appropriate use of the 22 antimicrobial drug; 23 ''(dd) submit a plan for reg- 24 istering the antimicrobial drug in 25 countries where an 1 unmet medical need exists, which 2 such plan may be consistent with 3 the Stewardship and Access Plan 4 (SAP) Development Guide 5 (2021); 6 ''(ee) subject to subpara- 7 graph (B), ensure a reliable drug 8 supply chain, thus leading to an 9 interruption of the supply of the 10 antimicrobial drug in the United 11 States for more than 60 days; or 12 ''(ff) make meaningful 13 progress toward completion of 14 Food and Drug Administration- 15 required postmarketing studies, 16 including such studies that are 17 evidence based; and 18 ''(II) other terms as determined 19 by the Secretary; and 20 ''(iii) if\u2014 21 ''(I) a phase 3 clinical study has 22 been initiated for the antimicrobial 23 drug; or 24 VerDate Nov 24 has 1 been approved under section 505(c) of 2 the Federal Food, Drug, and Cos- 3 metic Act or licensed under section 4 351(a). 5 ''(B) W AIVER .\u2014The requirement under 6 subparagraph (A)(ii)(I)(ee) may be waived in 7 the case that an emergency prohibits access to 8 a reliable drug supply chain. 9 ''(3) T RANSITIONAL GUIDANCE .\u2014Not later 10 than 120 days after the appointment of the initial 11 members of the Committee, the Secretary shall 12 issue, in consultation with the Committee, transi- 13 tional guidance outlining the antimicrobial drugs 14 that are eligible for transitional subscription con- 15 tracts under paragraph (1), the requirements to 16 enter into a transitional subscription contract under 17 paragraph (2), and the process by which drug devel- 18 opers can enter into transitional subscription con- 19 tracts with the Secretary under this subsection. 20 ''(4) P AYMENT OFFICE AND MECHANISM .\u2014Not 21 later than 30 days after the date of enactment of 22 this part, the Secretary shall determine the agency 23 or office in the Department of Health and Human 24 Services that will manage the transitional subscrip- 25 VerDate Nov 24 2008 including eligibility, requirements, 1 and contract amounts, during the period described 2 in paragraph (1). 3 ''(g) C RITICAL NEED ANTIMICROBIAL ADVISORY 4 GROUP .\u2014 5 ''(1) I N GENERAL .\u2014Not later than 30 days 6 after the appointment of all initial members of the 7 Committee, the Secretary, in collaboration with the 8 Committee, shall establish a Critical Need Anti- 9 microbial Advisory Group (referred to in this sub- 10 section as the 'Advisory Group') and appoint mem- 11 bers to the Advisory Group. 12 ''(2) M EMBERS .\u2014The members of the Advisory 13 Group shall include\u2014 14 ''(A) not fewer than 6 individuals who 15 are\u2014 16 ''(i) infectious disease specialists; or 17 ''(ii) other health experts with exper- 18 tise in researching antimicrobial resistance, 19 health economics, or commercializing anti- 20 microbial drugs; and 21 ''(B) not fewer than 5 patient advocates. 22 ''(3) C HAIR .\u2014The Secretary shall appoint one 23 of the members of the Advisory Group to serve as 24 the Chair. 25 VerDate Nov 24 2008 15:17 INTEREST .\u2014In appointing 1 members under paragraph (2), the Secretary shall 2 ensure that no member receives compensation in any 3 manner from a commercial or for-profit entity that 4 develops antimicrobials or that might benefit from 5 antimicrobial development. 6 ''(5) A PPLICABILITY OF FACA .\u2014Except as 7 in this subsection, the Federal Advi- 8 sory Committee Act shall apply to the Advisory 9 Group. 10 ''SEC. 399PP. CRITICAL NEED ANTIMICROBIAL DRUG APPLI-11 CATION AND SUBSCRIP- 12 TION 13 ''(a) I NGENERAL .\u2014 14 ''(1) S UBMISSION OF REQUEST .\u2014The sponsor 15 of an application under section 505(b) of the Fed- 16 eral Food, Drug, and Cosmetic Act or section 351(a) 17 for an antimicrobial drug may request that the Sec- 18 retary designate the drug as a critical need anti- 19 microbial. A request for such designation may be 20 submitted after the Secretary grants for such drug 21 an investigational new drug exemption under section 22 505(i) of the Federal Food, Drug, and Cosmetic Act 23 or section 351(a)(3), and shall be submitted not 24 later than 5 years after the date of approval under 25 VerDate Nov 24 2008 15:17 Drug, and Cos- 1 metic Act or licensure under section 351(a). 2 ''(2) C ONTENT OF REQUEST .\u2014A request under 3 paragraph (1) shall include information, such as 4 clinical, preclinical and postmarketing data, a list of 5 the favorable characteristics described in section 6 399OO(c)(2), and any other material that the Sec- 7 retary in consultation with the Committee requires. 8 ''(3) R EVIEW BY SECRETARY .\u2014The Secretary 9 shall promptly review all requests for designation 10 submitted under this subsection, assess all required 11 application components, and determine if the anti- 12 microbial drug is likely to meet the favorable charac- 13 teristics identified in the application upon the com- 14 pletion of clinical development. After review, the Sec- 15 retary shall approve or deny each request for des- 16 ignation not later than 90 days after receiving a re- 17 quest. If the Secretary approves a request, it shall 18 publish the value of the contract that the critical 19 need antimicrobial developer would be eligible to re- 20 ceive if such developer successfully demonstrates 21 that the drug meets the maximum value of the fa- 22 vored characteristics listed in the application. 23 ''(4) L ENGTH OF DESIGNATION PERIOD .\u2014A 24 designation granted under this section shall be in ef- 25 VerDate Nov 24 2008 a period of 10 years after the date that the 1 designation is approved, and shall remain in effect 2 for such period even if the infection treated by such 3 drug is later removed from the list of infections 4 under section 399OO(c)(1). 5 ''(5) S UBSEQUENT REVIEWS .\u2014No sooner than 6 2 years after a designation approval or denial under 7 subsection (3), the sponsor may request a subse- 8 quent review to re-evaluate the value of a contract 9 to include any new information. 10 ''(b) D EVELOPMENT OF DESIGNATED DRUGS .\u2014If a 11 critical need antimicrobial designation is granted during 12 clinical development of an antimicrobial drug, the Sec-13 retary may work with the sponsor to maximize the oppor-14 tunity for the sponsor to successfully demonstrate that the 15 antimicrobial drug possesses the favored characteristics of 16 high-monetary valued products identified under section 17 399OO(c)(2). 18 ''(c) A PPROPRIATE USE OF CRITICAL NEED ANTI- 19 MICROBIAL .\u2014 20 ''(1) I N GENERAL .\u2014The sponsor of an anti- 21 microbial drug that receives designation under sub- 22 section (a) shall within 90 days of such designation, 23 submit to the Secretary a plan for appropriate use 24 of diagnostics, in order for the Secretary and Com- 25 VerDate Nov 24 2008 15:17 consider such plan in developing clinical 1 guidelines. An appropriate use plan\u2014 2 ''(A) shall include\u2014 3 ''(i) the appropriate use of the drug; 4 and 5 ''(ii) the appropriate use of diagnostic 6 tools, where available, such as diagnostic 7 testing for biomarkers related to anti- 8 microbial-resistant pathogens, or other tar- 9 geted diagnostic approaches, to inform use 10 of the drug; and 11 ''(B) may be developed in partnership with 12 the Secretary, infectious disease experts, diag- 13 nostic experts or developers, laboratory experts, 14 or another entity. 15 ''(2) C ONSULTATION .\u2014The Secretary shall con- 16 sult with relevant professional societies and the Crit- 17 ical Need Antimicrobial Advisory Group established 18 under section 399OO(g) to ensure that clinical 19 guidelines issued by the Secretary under paragraph 20 (3), with respect to an antimicrobial drug designated 21 under subsection (a), includes the use of appropriate 22 diagnostic approaches, taking into consideration the 23 diagnostic plan submitted by a sponsor under para- 24 graph (1). 25 VerDate Nov 24 2008 OF CLINICAL GUIDELINES .\u2014 1 Not later than 1 year after the Secretary makes the 2 first designation under subsection (a), and not less 3 than every 3 years thereafter, the Secretary shall 4 publish clinical guidelines in consultation with rel- 5 evant professional societies with respect to each anti- 6 microbial drug that has been approved or licensed as 7 described in subsection (a)(1) and that has been des- 8 ignated under subsection (a), which guidelines shall 9 set forth the evidence-based recommendations for 10 prescribing the drug, in accordance with the submis- 11 sions of the sponsor under paragraph (1) and after 12 consultation under paragraph (2), as appropriate. 13 ''SEC. 399QQ. SUBSCRIPTION CONTRACTS. 14 ''(a) A PPLICATION FOR A SUBSCRIPTION CON- 15 TRACT .\u2014 16 ''(1) S UBMISSION OF APPLICATIONS .\u2014After ap- 17 proval under section 505(c) of the Federal Food, 18 Drug, and Cosmetic Act or licensure under section 19 351(a), the sponsor of an antimicrobial drug des- 20 ignated as a critical need antimicrobial under section 21 399PP may submit an application for a subscription 22 contract with the Secretary, under a procedure es- 23 tablished by the Secretary. 24 VerDate Nov 24 2008 retary shall, in consultation with the Committee\u2014 2 ''(A) review all applications for subscrip- 3 tion contracts under paragraph (1) and assess 4 all required application components; 5 ''(B) determine the extent to which the 6 critical need antimicrobial meets the favored 7 characteristics identified under section 8 399OO(c)(2), and deny any application for a 9 drug that meets none of such characteristics; 10 and 11 ''(C) assign a monetary value to the con- 12 tract based on the regulations developed under 13 section 399OO(d). 14 ''(b) C RITERIA .\u2014To qualify for a subscription con- 15 tract under this section, the sponsor of an antimicrobial 16 drug designated as a critical need antimicrobial shall agree 17 to\u2014 18 ''(1) ensure commercial and Federal availability 19 of the antimicrobial drug within 30 days of receiving 20 first payment under the contract, and sufficient sup- 21 ply for susceptibility device manufacturers; 22 ''(2) identify, track, and publicly report drug 23 resistance data and trends using available data re- 24 lated to the antimicrobial drug; 25 implement education and com- 1 munications strategies, including communications 2 for individuals with limited English proficiency and 3 individuals with disabilities, for health care profes- 4 sionals and patients about appropriate use of the 5 antimicrobial drug; 6 ''(4) submit an appropriate use assessment to 7 the Secretary, Committee, Food and Drug Adminis- 8 tration, and Centers for Disease Control and Pre- 9 vention every 2 years regarding use of the anti- 10 microbial drug, including how the drug is being mar- 11 keted; 12 ''(5) submit a plan for registering the drug in 13 additional countries where an unmet medical need 14 exists; 15 ''(6) ensure a reliable drug supply chain, where 16 any interruption to the supply chain will not last for 17 more than 60 days in the United States; 18 ''(7) complete any postmarketing studies re- 19 quired by the Food and Drug Administration in a 20 timely manner; 21 ''(8) produce the drug at a reasonable volume 22 determined with the Secretary to ensure patient ac- 23 cess to the drug; 24 VerDate Nov 24 the drug at a price that is not lower 1 than a comparable generic drug; 2 ''(10) abide by the manufacturing and environ- 3 mental best practices in the supply chain to ensure 4 that there is no discharge into, or contamination of, 5 the environment by antimicrobial agents or products 6 as a result of the manufacturing process; and 7 ''(11) abide by other terms as the Secretary 8 may require. 9 ''(c) A MOUNT AND TERMS OF CONTRACTS .\u2014 10 ''(1) A MOUNTS .\u2014A subscription contract under 11 this section shall be for the sale to the Secretary of 12 any quantity of the antimicrobial drug needed over 13 the term of the contract under paragraph (2), at an 14 agreed upon price, for a total projected amount de- 15 termined by the Secretary that is not less than 16 $750,000,000 and not more than $3,000,000,000, 17 adjusted for inflation, accounting for the favored 18 characteristics of the drug, as determined by the 19 Secretary, in consultation with the Committee, under 20 subsection (a)(2), and shall be allocated from the 21 amount made available under section 399SS(a). Not 22 later than 6 months after the subscription contract 23 is granted under subsection (a), the Secretary shall 24 provide payments for purchased drugs in install- 25 VerDate Nov 24 2008 by the Secretary in consultation 1 with the sponsor of the antimicrobial drug and in ac- 2 cordance with subsection (d)(3). Funds received by 3 the sponsor shall be used to support criteria quali- 4 fication under subsection (b), the completion of post- 5 marketing clinical studies, manufacturing, other pre- 6 clinical and clinical activities, or other activities 7 agreed to by the Secretary and sponsor in the con- 8 tract. 9 ''(2) T ERMS .\u2014 10 ''(A) I NITIAL TERM .\u2014The initial term of a 11 contract under this subsection shall be no less 12 than 5 years or greater than the greater of 10 13 years or the remaining period of time during 14 which the sponsor has patent protections or a 15 remaining exclusivity period with respect to the 16 antimicrobial drug in the United States, as list- 17 ed in the publication of the Food and Drug Ad- 18 ministration entitled 'Approved Drug Products 19 with Therapeutic Equivalence Evaluations'. 20 Payments may be in equal annual installments 21 with the option to redeem 50 percent of the last 22 year's reimbursement in year 1 of the contract 23 in order to offset costs of establishing manufac- 24 turing capacity, or another subscription ar- 25 VerDate Nov 24 2008 15:17 which the Secretary and sponsor 1 agree. Subscription contracts shall remain in ef- 2 fect for such period even if the infection treated 3 by such antimicrobial drug is later removed 4 from the list of infections under section 5 399OO(c)(1). 6 ''(B) E XTENSION OF CONTRACTS .\u2014The 7 Secretary may extend a subscription contract 8 with a sponsor under this subsection beyond the 9 initial contract period. A single contract exten- 10 sion may be in effect not later than the date on 11 which all periods of exclusivity granted by the 12 Food and Drug Administration expire and shall 13 be in an amount not to exceed $25,000,000 per 14 year. All other terms of an extended contract 15 shall be the same as the terms of the initial 16 contract. The total amount of funding used on 17 such contract extensions shall be no more than 18 $1,000,000,000, and shall be allocated from the 19 amount made available under section 399SS. 20 ''(C) M ODIFICATION OF CONTRACTS .\u2014The 21 Secretary or sponsor, 1 year after the start of 22 the contract period under this subsection and 23 every 2 years thereafter, may request a modi- 24 fication of the amount of the contract based on 25 VerDate Nov 24 2008 15:17 in section 399OO(c)(2). 2 ''(3) A DJUSTMENT .\u2014In the case of an anti- 3 microbial drug that received a transitional subscrip- 4 tion contract under section 399OO(f), the amount of 5 a subscription contract for such drug under this sec- 6 tion shall be reduced by the amount of the transi- 7 tional subscription contract under such section 8 399OO(f) for such drug. 9 ''(4) C ONTRACTS FOR GENERIC AND BIO - 10 SIMILAR VERSIONS .\u2014Notwithstanding any other 11 provision in this part, the Secretary may award a 12 subscription contract under this section to a manu- 13 facturer of a generic or biosimilar version of an anti- 14 microbial drug for which a subscription contract has 15 been awarded under this section. Such contracts 16 shall be awarded in accordance with a procedure, in- 17 cluding for determining the terms and amounts of 18 such contracts, established by the Secretary. 19 ''(d) A NNUAL ANTIMICROBIAL DRUG SPONSOR REV- 20 ENUE LIMITATIONS .\u2014 21 ''(1) R EPORTING REQUIREMENT .\u2014 22 ''(A) I N GENERAL .\u2014Not later than a date 23 determined appropriate by the Secretary fol- 24 lowing the end of each calendar year, and not 25 VerDate Nov 24 2008 15:17 months after the end of each cal- 1 endar year, the head (or a designee of such 2 head) of each Federal agency carrying out a 3 specified government program shall, in accord- 4 ance with this paragraph, report to the Sub- 5 scription Contract Office established under sec- 6 tion 399OO(d)(3) the total prescription drug 7 sales for each applicable antimicrobial drug 8 under contract with respect to such program for 9 such calendar year. 10 ''(B) M EDICARE PART D PROGRAM .\u2014For 11 purposes of subparagraph (A), the Secretary 12 shall report, for each applicable antimicrobial 13 drug covered under part D of title XVIII of the 14 Social Security Act, the product of\u2014 15 ''(i) the per-unit ingredient cost, as 16 reported to the Secretary by prescription 17 drug plans and Medicare Advantage pre- 18 scription drug plans, minus any per-unit 19 rebate, discount, or other price concession 20 provided by the sponsor of such applicable 21 antimicrobial drug, as reported to the Sec- 22 retary by the prescription drug plans and 23 the Medicare Advantage prescription drug 24 plans; and 25 VerDate Nov 24 2008 such ap- 1 plicable antimicrobial drug paid for under 2 such part D. 3 ''(C) M EDICARE PART B PROGRAM .\u2014 4 ''(i) I N GENERAL .\u2014For purposes of 5 subparagraph (A), the Secretary shall re- 6 port, for each applicable antimicrobial drug 7 covered under part B of title XVIII of the 8 Social Security Act, the product of\u2014 9 ''(I) the per-unit average sales 10 price (as defined in section 1847A(c) 11 of such Act) or the per-unit payment 12 rate under such part B for a sepa- 13 rately paid prescription drug without 14 a reported average sales price; and 15 ''(II) the number of units of such 16 applicable antimicrobial drug paid for 17 under such part B. 18 ''(ii) U NITS AND ALLOCATED 19 PRICES .\u2014The Secretary shall establish a 20 process for determining the units and the 21 allocated price for purposes of this sub- 22 paragraph for those applicable anti- 23 microbial drugs that are not separately 24 VerDate Nov 24 2008 15:17 or for which National Drug Codes 1 are not reported. 2 ''(D) M EDICARE PART A PROGRAM .\u2014 3 ''(i) I N GENERAL .\u2014For purposes of 4 subparagraph (A), the Secretary shall re- 5 port, for each applicable antimicrobial drug 6 covered under part A of title XVIII of the 7 Social Security Act, the product of\u2014 8 ''(I) the per-unit price under 9 such part A for the antimicrobial 10 drug; and 11 ''(II) the number of units of such 12 antimicrobial drug paid for under 13 such part A. 14 ''(ii) S PECIAL RULE .\u2014For purposes of 15 clause (i), the Secretary shall establish a 16 process for determining the units and the 17 allocated price for those prescription drugs 18 that are not separately payable or for 19 which National Drug Codes are not re- 20 ported in the diagnosis-related groups. 21 ''(E) M EDICAID PROGRAM .\u2014Under the au- 22 thority of section 1902(a)(6) of the Social Secu- 23 rity Act, the Secretary shall require each State 24 that makes medical assistance available under 25 VerDate Nov 24 2008 15:17 plan under title XIX of such Act (or 1 any waiver of such plan) for an applicable anti- 2 microbial drug (including, if applicable, any 3 such drug which is a covered outpatient drug 4 under a rebate agreement entered into under 5 section 1927 of such Act) to report, in a form 6 consistent with a standard reporting format es- 7 tablished by the Secretary, not later than the 8 date determined under subparagraph (A)\u2014 9 ''(i) information on the total number 10 of units of each dosage form and strength 11 and package size of each applicable anti- 12 microbial drug dispensed during the pre- 13 ceding calendar year under such State plan 14 or waiver (including any such drugs dis- 15 pensed to an individual enrolled with a 16 medicaid managed care organization or 17 other specified entity (as such terms are 18 defined in section 1903(m) of such Act)); 19 and 20 ''(ii) with respect to each dosage form 21 and strength and package size of each such 22 drug, the amount equal to\u2014 23 ''(I) the product of\u2014 24 number of 1 units dispensed under the State 2 plan or waiver during the pre- 3 ceding calendar year (as deter- 4 mined under clause (i)); and 5 ''(bb) the per-unit ingredient 6 cost paid by the State for each 7 such unit; minus 8 ''(II) any discounts or other price 9 concessions provided and rebates paid 10 to the State with respect to the dos- 11 age form and strength and package 12 size of such drug and such calendar 13 year (including rebates paid under a 14 rebate agreement under section 1927 15 of such Act and any State supple- 16 mental rebates paid under a supple- 17 mental rebate agreement). 18 ''(F) D EPARTMENT OF VETERANS AF - 19 FAIRS .\u2014For purposes of subparagraph (A), the 20 Secretary of Veterans Affairs shall report the 21 total amount paid for each applicable anti- 22 microbial drug procured by the Veterans Health 23 Administration for individuals who receive 24 health care from the Administration. 25 VerDate Nov 24 2008 15:17 TRICARE PROGRAM .\u2014For purposes of subpara- 2 graph (A), the Secretary of Defense shall report 3 the sum of\u2014 4 ''(i) the total amount paid for each 5 applicable antimicrobial drug procured by 6 the Department of Defense for individuals 7 who receive health care from the Depart- 8 ment; and 9 ''(ii) for each applicable antimicrobial 10 drug dispensed under the TRICARE retail 11 pharmacy program under section 12 1074g(a)(2)(E)(ii) of title 10, United 13 States Code, the product of\u2014 14 ''(I) the per-unit ingredient cost, 15 minus any per-unit rebate paid by the 16 sponsor of the applicable antimicrobial 17 drug; and 18 ''(II) the number of units of such 19 applicable antimicrobial drug dis- 20 pensed under such program. 21 ''(H) D EPARTMENT OF HOMELAND SECU - 22 RITY.\u2014For purposes of subparagraph (A), the 23 Secretary of Homeland Security shall report the 24 total amount paid for each applicable anti- 25 VerDate Nov 24 2008 procured by the Department of 1 Homeland Security for individuals who receive 2 health care through a program carried out by 3 the Department. 4 ''(I) B UREAU OF PRISONS .\u2014For purposes 5 of subparagraph (A), the Director of the Bu- 6 reau of Prisons shall report the total amount 7 paid for each applicable antimicrobial drug pro- 8 cured by the Bureau of Prisons for individuals 9 who receive health care through the Bureau. 10 ''(J) I NDIAN HEALTH SERVICE .\u2014For pur- 11 poses of subparagraph (A), the Secretary, act- 12 ing through the Indian Health Service, shall re- 13 port the total amount paid for each applicable 14 antimicrobial drug procured by the Service for 15 individuals who receive health care through the 16 Service. 17 ''(2) R EGULATIONS .\u2014Not later than 1 year 18 after the date of enactment of this part, the Sec- 19 retary, in consultation with the heads of Federal 20 agencies carrying out specified government pro- 21 grams, shall issue regulations to assist such heads 22 (or their designees) in carrying out the requirements 23 under this section. 24 VerDate Nov 24 2008 15:17 CONTRACT ADJUSTMENT .\u2014 1 Pursuant to the contract entered into under this sec- 2 tion with respect to an applicable antimicrobial drug, 3 for each year of the term of such contract, the Sec- 4 retary shall, not earlier than 6 months after the end 5 of each calendar year, subtract from the payment in- 6 stallments determined for such contract under sub- 7 section (c)(1) for such year the revenue of the spon- 8 sor of such drug from the previous year from sales 9 of the applicable antimicrobial drug reported under 10 paragraph (1) for specified government programs. 11 ''(4) D EFINITIONS .\u2014In this subsection: antimicrobial 14 drug' means an antimicrobial drug for which 15 the sponsor of such drug receives a subscription 16 contract under subsection (a). 17 ''(B) S PECIFIED GOVERNMENT PRO - 18 GRAM .\u2014The term 'specified government pro- 19 gram' means\u2014 20 ''(i) the Medicare part D program 21 under part D of title XVIII of the Social 22 Security Act; 23 ''(ii) the Medicare Part B program 24 under part B of such title XVIII; 25 VerDate Nov 24 2008 Medicare Part A program 1 under part A of such title XVIII; 2 ''(iv) the Medicaid program estab- 3 lished under title XIX of the Social Secu- 4 rity Act and includes, with respect to a 5 State, any waiver in effect with respect to 6 such program; 7 ''(v) any program under which pre- 8 scription drugs are procured by the De- 9 partment of Veterans Affairs; 10 ''(vi) any program under which pre- 11 scription drugs are procured by the De- 12 partment of Defense; 13 ''(vii) the TRICARE retail pharmacy 14 program under section 1074g(a)(2)(E)(ii) 15 of title 10, United States Code; 16 ''(viii) any program under which pre- 17 scription drugs are procured by the De- 18 partment of Homeland Security; 19 ''(ix) any program under which pre- 20 scription drugs are procured by the Bu- 21 reau of Prisons; or 22 ''(x) any program under which pre- 23 scription drugs are procured by the Indian 24 Health Service. 25 VerDate Nov 24 2008 15:17 Sec- 1 retary shall cease any payment installments under a con-2 tract under this section if\u2014 3 ''(1) the sponsor\u2014 4 ''(A) permanently withdraws the anti- 5 microbial drug from the market in the United 6 States; 7 ''(B) fails to meet criteria under subsection 8 (b); or 9 ''(C) does not complete a postmarket study 10 required by the Food and Drug Administration 11 during the length of the term of the contract; 12 ''(2) the annual international and private insur- 13 ance market revenues with respect to an anti- 14 microbial drug (not counting any subscription reve- 15 nues from any source pursuant to a contract under 16 this section or other international or private entities) 17 exceed 5 times the average annual amount of the 18 subscription contract paid by the Secretary as cer- 19 tified by the sponsor annually; or 20 ''(3) if the total revenue of the sponsor from 21 specified government programs, as defined in sub- 22 section (d)(4), for a year exceeds the amount of the 23 subscription contract paid by the Secretary for that 24 year. 25 VerDate Nov 24 2008 15:17 AND INTERNATIONAL PAYER 1 PARTICIPATION .\u2014The Secretary shall make efforts to in- 2 crease the participation of domestic private payors and 3 international payors in subscription contracts or other 4 types of value-based arrangements that are similar to the 5 subscription contracts authorized under this section. 6 ''SEC. 399RR. ENCOURAGING APPROPRIATE USE OF ANTI-7 BIOTICS AND COMBATING RESISTANCE. 8 ''(a) E STABLISHMENT OF HOSPITAL GRANT PRO- 9 GRAM .\u2014 10 ''(1) I N GENERAL .\u2014Not later than 1 year after 11 the date of enactment of this part, the Secretary and 12 the Director of the Centers for Disease Control and 13 Prevention shall coordinate with the Administrator 14 of the Health Resources and Services Administra- 15 tion, the Administrator of the Centers for Medicare 16 & Medicaid Services, the National Coordinator for 17 Health Information Technology, and other relevant 18 agencies, to establish a grant program under the 19 Centers for Disease Control and Prevention to sup- 20 port hospital and other inpatient facility efforts\u2014 21 ''(A) to judiciously use antimicrobial drugs, 22 such as by establishing or implementing appro- 23 priate use programs, including infectious dis- 24 ease telehealth programs, using appropriate di- 25 VerDate Nov 24 2008 care-associated infec- 2 tion reporting, and monitoring antimicrobial re- 3 sistance; and 4 ''(B) to participate in the National 5 Healthcare Safety Network Antimicrobial Use 6 and Resistance Module or the Emerging Infec- 7 tions Program Healthcare-Associated Infections 8 Community Interface activity of the Centers for 9 Disease Control and Prevention or a similar re- 10 porting program, as specified by the Secretary, 11 relating to antimicrobial drugs. 12 ''(2) P RIORITIZATION .\u2014In awarding grants 13 under paragraph (1), the Secretary shall prioritize 14 hospitals without an existing program to judiciously 15 use antimicrobial drugs, subsection (d) hospitals (as 16 defined in subparagraph (B) of section 1886(d)(2) 17 of the Social Security Act that are located in rural 18 areas (as defined in subparagraph (D) of such sec- 19 tion), critical access hospitals (as defined in section 20 1861(mm)(1) of such Act), hospitals serving Tribal- 21 populations, and safety-net hospitals. 22 ''(3) F UNDING .\u2014Of the amounts appropriated 23 under section 399SS, the Secretary shall reserve 24 $500,000,000 to carry out this subsection. 25 VerDate Nov 24 AND REPORTING OF ANTIBIOTIC 1 USE AND RESISTANCE .\u2014 2 ''(1) I N GENERAL .\u2014The Secretary, acting 3 through the Director of the Centers for Disease 4 Control and Prevention, shall use the National 5 Healthcare Safety Network and other appropriate 6 surveillance systems to assess\u2014 7 ''(A) appropriate conditions, outcomes, and 8 measures causally related to antibacterial resist- 9 ance, including types of infections, the causes 10 for infections, and whether infections are ac- 11 quired in a community or hospital setting, in- 12 creased lengths of hospital stay, increased costs, 13 and rates of mortality; and 14 ''(B) changes in bacterial resistance to 15 antimicrobial drugs in relation to patient out- 16 comes, including changes in percent resistance, 17 prevalence of antibiotic-resistant infections, and 18 other such changes. 19 ''(2) A NTIBIOTIC USE DATA .\u2014The Secretary, 20 acting through the Director of the Centers for Dis- 21 ease Control and Prevention, shall work with Fed- 22 eral agencies (including the Department of Veterans 23 Affairs, the Department of Defense, the Department 24 of Homeland Security, the Bureau of Prisons, the 25 VerDate Nov 24 2008 15:17 Health Service, and the Centers for Medicare 1 & Medicaid Services), private vendors, health care 2 organizations, pharmacy benefit managers, and 3 other entities as appropriate to obtain reliable and 4 comparable human antibiotic drug consumption data 5 (including, as available and appropriate, volume an- 6 tibiotic distribution data and antibiotic use data, in- 7 cluding prescription data) by State or metropolitan 8 areas. 9 ''(3) A NTIBIOTIC RESISTANCE TREND DATA .\u2014 10 The Secretary, acting through the Director of the 11 Centers for Disease Control and Prevention, shall in- 12 tensify and expand efforts to collect antibiotic resist- 13 ance data and encourage adoption of the Antibiotic 14 Use and Resistance Module within the National 15 Healthcare Safety Network among all health care fa- 16 cilities across the continuum of care, including, as 17 appropriate, acute care hospitals, dialysis facilities, 18 nursing homes, ambulatory surgical centers, and 19 other ambulatory health care settings in which anti- 20 microbial drugs are routinely prescribed. The Sec- 21 retary shall seek to collect such data from electronic 22 medication administration reports and laboratory 23 systems to produce the reports described in para- 24 graph (4). 25 VerDate Nov 24 2008 OF DATA .\u2014The 1 Secretary, acting through the Director of the Cen- 2 ters for Disease Control and Prevention, shall, for 3 the purposes of improving the monitoring of impor- 4 tant trends in patient outcomes in relation to anti- 5 bacterial resistance\u2014 6 ''(A) make the data derived from surveil- 7 lance under this subsection publicly available 8 through reports issued on a regular basis that 9 is not less than annually; and 10 ''(B) examine opportunities to make such 11 data available in near real time. 12 ''SEC. 399SS. APPROPRIATIONS. 13 ''(a) I NGENERAL .\u2014To carry out this part, there are 14 hereby appropriated to the Secretary, out of amounts in 15 the Treasury not otherwise appropriated, 16 $11,000,000,000, for fiscal year 2022, to remain available 17 until expended. 18 ''(b) E MERGENCY DESIGNATION .\u2014 19 ''(1) I N GENERAL .\u2014The amounts provided by 20 this section are designated as an emergency require- 21 ment pursuant to section 4(g) of the Statutory Pay- 22 As-You-Go Act of 2010. 23 ''(2) D ESIGNATION IN SENATE .\u2014In the Senate, 24 this section is designated as an emergency require- 25 VerDate Nov 24 2008 section 4112(a) of H. Con. Res. 1 71 (115th Congress), the concurrent resolution on 2 the budget for fiscal year 2018. 3 ''SEC. 399TT. STUDIES AND REPORTS. 4 ''(a) I NGENERAL .\u2014Not later than 6 years after the 5 date of enactment of this part, the Comptroller General 6 of the United States shall complete a study on the effec-7 tiveness of this part in developing priority antimicrobial 8 drugs. Such study shall examine the indications for, usage 9 of, development of resistance with respect to, and private 10 and societal value of critical need antimicrobial drugs, and 11 the impact of the programs under this part on patients 12 and markets of critical need antimicrobial drugs. The 13 Comptroller General shall report to the Committee on 14 Health, Education, Labor, and Pensions of the Senate and 15 the Committee on Energy and Commerce of the House 16 of Representatives on the findings of such study. 17 ''(b) A NTIBIOTIC USE IN THE UNITED STATES ; AN- 18 NUAL REPORTS .\u2014The Director of the Centers for Disease 19 Control and Prevention shall, each year, update the report 20 entitled 'Antibiotic Use in the United States' to include 21 updated information on progress and opportunities with 22 respect to data, programs, and resources for prescribers 23 to promote appropriate use of antimicrobial drugs. 24 VerDate Nov 24 2008 .\u2014 1 Not later than 3 years after the date of enactment of this 2 part, the Director of the Centers for Disease Control and 3 Prevention shall publish a report on antimicrobial prophy-4 lactics. 5 ''SEC. 399UU. 'antimicrobial drug'\u2014 8 ''(A) means, subject to subparagraph (B), 9 a product that is\u2014 10 ''(i) a drug that directly inhibits rep- 11 lication of or kills bacteria or fungi rel- 12 evant to the proposed indication at con- 13 centrations likely to be attainable in hu- 14 mans to achieve the intended therapeutic 15 effect; or 16 ''(ii) a biological product that acts di- 17 rectly on bacteria or fungi or on the sub- 18 stances produced by such bacteria or fungi; 19 and 20 ''(B) does not include\u2014 21 ''(i) a drug that achieves the effect de- 22 scribed by subparagraph (A)(i) only at a 23 concentration that cannot reasonably be 24 VerDate Nov 24 2008 15:17 1 pated toxicity; or 2 ''(ii) a vaccine; and 3 ''(2) the term 'Committee' means the Com- 4 mittee on Critical Need Antimicrobials established 5 under section 399OO.''. 6 TITLE II\u2014PATIENTS AND 7 CAREGIVERS 8 SEC. 201. EDUCATIONAL PROGRAMS AND TRAINING FOR 9 CAREGIVERS. 10 Part D of title VII of the Public Health Service Act 11 (42 U.S.C. 294 et seq.) is amended by adding at the end 12 the following: 13 ''SEC. 760A. EDUCATIONAL PROGRAMS AND TRAINING FOR 14 CAREGIVERS. 15 ''(a) I NGENERAL .\u2014The Secretary may award grants 16 for educational programs and training for caregivers to 17 learn skills to empower them\u2014 18 ''(1) to be a member of a care team; and 19 ''(2) to complement a clinical visit. 20 ''(b) T YPES OF PROGRAMS AND TRAINING .\u2014Edu- 21 cational programs and training funded under subsection 22 (a) may include\u2014 23 ''(1) specialized training in medication adher- 24 ence and injections; ensure 1 ence to physical, occupational, speech, and 2 habilitative regimens; 3 ''(3) nutritional compliance; 4 7 ''(5) caregiver health self-management; and 8 ''(6) other services provided in the home. 9 ''(c) N ON-DUPLICATION .\u2014The Secretary may not use 10 the same requirements under this section for a grant, con-11 tract, or cooperative agreement under the Geriatric Work-12 force Enhancement Program under section 753 of the 13 Public Health Service Act (42 U.S.C. 294c). 14 ''(d) C AREGIVER DEFINED .\u2014In this section, the 15 term 'caregiver' means an adult family member or other 16 individual who has a significant relationship with, and who 17 provides a broad range of assistance to, an individual with 18 a chronic or other health condition, disability, or func-19 tional limitation. 20 ''(e) A UTHORIZATION OF APPROPRIATIONS .\u2014To 21 carry out this section, there is authorized to be appro-22 priated $25,000,000 for each of fiscal years 2022 through 23 2024.''. 24 VerDate Nov 24 202. INCREASING HEALTH LITERACY TO PROMOTE 1 BETTER OUTCOMES FOR PATIENTS. 2 (a) I NGENERAL .\u2014Not later than one year after the 3 date of the enactment of this Act, the Secretary of Health 4 and Human Services, acting through the Administrator of 5 the Centers for Medicare & Medicaid Services, shall issue 6 a request for information to solicit recommendations on 7 ways the Centers for Medicare & Medicaid Services can 8 work with stakeholders of the Federal health care pro-9 grams (as defined in section 1128B(f) of the Social Secu-10 rity Act (42 U.S.C. 1320a-7b(f))) to promote increased 11 patient and family caregiver health literacy, including rec-12 ommendations for\u2014 13 (1) identifying culturally competent, evidence- 14 based interventions that have been proven to im- 15 prove health literacy in populations served by such 16 programs; 17 (2) identifying evidence-based health literacy 18 approaches that can be used by the Medicare pro- 19 gram under title XVIII of the Social Security Act 20 (42 U.S.C. 1395 et seq.), a State plan (or waiver of 21 such plan) under title XIX of such Act (42 U.S.C. 22 1396 et seq.), a State child health plan (or waiver 23 of such plan) under title XXI of such Act (42 24 U.S.C. 1397aa et seq.), or health care providers par- 25 ticipating in such program under such title XVIII, 26 VerDate Nov 24 2008 a State plan (or waiver of such plan) under 1 such title XIX, or under a State child health plan 2 (or waiver of such plan) under such title XXI, and 3 that\u2014 4 (A) have been proven to, or show promise 5 to, reduce costs to individuals enrolled under a 6 State plan (or waiver of such plan) under such 7 title XIX, or under a State child health plan (or 8 waiver of such plan) under such title XXI, re- 9 spectively, and reduce expenditures under such 10 respective titles; or 11 (B) have been proven to increase patient 12 and family caregiver satisfaction or improve the 13 quality of care for at-risk populations, including 14 holistic and non-medication-based forms of care; 15 (3) how the Centers for Medicare & Medicaid 16 Services can encourage the use of evidence-based 17 health literacy interventions through payment poli- 18 cies under the Medicare program under title XVIII 19 of the Social Security Act (42 U.S.C. 1395 et seq.), 20 a State plan under title XIX of such Act (42 U.S.C. 21 1396 et seq.), a State child health plan under title 22 XXI of such Act (42 U.S.C. 1397 et seq.); and 23 (4) improving patient and family caregiver 24 health literacy with respect to health insurance, in- 25 VerDate Nov 24 2008 15:17 co-insurance, co-payments, and dif- 2 ferences between payors. 3 SEC. 203. INCREASING DIVERSITY IN CLINICAL TRIALS. 4 (a) U PDATED REPORTING ON INCLUSION OF DEMO- 5 GRAPHIC SUBGROUPS .\u2014The Secretary of Health and 6 Human Services, acting through the Commissioner of 7 Food and Drugs, shall\u2014 8 (1) not later than 90 days after the date of en- 9 actment of this Act, submit to the Food and Drug 10 Administration, and provide to the Congress, an up- 11 dated version of the report under section 907(a) of 12 the Food and Drug Administration Safety and Inno- 13 vation Act (Public Law 115-52); and 14 (2) not later than 1 year after the publication 15 of the updated report pursuant to paragraph (1), 16 publish on the website of the Food and Drug Ad- 17 ministration, and provide to the Congress, an up- 18 dated version of the action plan under section 19 907(b) of such Act. 20 (b) GAO S TUDY ON BARRIERS TO PARTICIPATION .\u2014 21 Not later than 1 year after the date of enactment of this 22 Act, the Comptroller General of the United States shall\u2014 23 (1) complete a study\u2014 24 VerDate Nov 24 to review how the Department of 1 Health and Human Services addresses barriers 2 to participation by individuals from underrep- 3 resented populations in conducting or sup- 4 porting clinical trials; and 5 (B) to formulate recommendations for ad- 6 dressing such barriers; and 7 (2) submit a report to the Congress on the re- 8 sults of such study. 9 (c) P UBLIC AWARENESS CAMPAIGN .\u2014The Secretary 10 of Health and Human Services shall\u2014 11 (1) carry out a public awareness campaign to 12 increase awareness and understanding, particularly 13 in minority communities, of\u2014 14 (A) upcoming and ongoing clinical trials; 15 (B) how to enroll as subjects in such clin- 16 ical trials; and 17 (C) the availability of databases and other 18 resources relevant to clinical trial enrollment, 19 such as ClinicalTrials.gov; and 20 (2) in carrying out such campaign, utilize a va- 21 riety of communication channels, including through 22 use of the explanation of Medicare benefits under 23 section 1806 of the Social Security Act (42 U.S.C. 24 1395b-7). 25 VerDate Nov 24 FOR MAKING CLINICAL TRIALS .GOV 1 MOREUSER-FRIENDLY .\u2014 2 (1) I N GENERAL .\u2014The Secretary of Health and 3 Human Services shall convene a permanent task 4 force to propose, on a biennial basis, recommenda- 5 tions for improving ClinicalTrials.gov by making it 6 more user-friendly, including for patients. 7 (2) M EMBERSHIP .\u2014The membership of the 8 task force shall include representatives of\u2014 9 (A) the National Institutes of Health; 10 (B) the Food and Drug Administration; 11 (C) academic researchers; and 12 (D) patient organizations. 13 (e) D EFINITION .\u2014In this section, the term 14 ''ClinicalTrials.gov'' refers to the data bank described in 15 section 402(i) of the Public Health Service Act (42 U.S.C. 16 282(i)). 17 SEC. 204. PATIENT EXPERIENCE DATA. 18 (a) P OLICY .\u2014Section 569C of the Federal Food, 19 Drug, and Cosmetic Act (21 U.S.C. 360bbb-8c) is amend-20 ed\u2014 21 (1) by redesignating subsections (b) and (c) as 22 subsections (c) and (d), respectively; and 23 (2) by inserting after subsection (a) the fol- 24 lowing new subsection: DATA.\u2014 ''(1) I N GENERAL .\u2014The Secretary shall\u2014 3 ''(A) for any drug for which an exemption 4 is granted for investigational use under section 5 505(i) of this Act or section 351(a) of the Pub- 6 lic Health Service Act, require the sponsor of 7 the drug to collect standardized patient experi- 8 ence data as part of the clinical trials conducted 9 pursuant to such exemption; 10 ''(B) require any application for the ap- 11 proval or licensing of such drug under section 12 505(b) of this Act or section 351(a) of the Pub- 13 lic Health Service Act to include\u2014 14 ''(i) the standardized patient experi- 15 ence data so collected; and 16 ''(ii) such related information as the 17 Secretary may require; and 18 ''(C) consider patient experience data and 19 related information that is submitted pursuant 20 to subparagraph (B) in deciding whether to ap- 21 prove or license, as applicable, the drug in- 22 volved. 23 ''(2) A PPLICABILITY .\u2014Paragraph (1) applies 24 only with respect to drugs for which a request for 25 VerDate Nov 24 2008 15:17 paragraph (1)(A) is sub- 1 mitted on or after the date of enactment of the 2 Cures 2.0 Act, or an application under section 3 505(b) of this Act or section 351(a) of the Public 4 Health Service Act is filed, as applicable, on or after 5 the day that is 2 years after the date of enactment 6 of the Cures 2.0 Act.''. 7 (b) R EGULATIONS .\u2014Not later than 1 year after the 8 date of enactment of this Act, the Secretary of Health and 9 Human Services, acting through the Commissioner of 10 Food and Drugs, shall promulgate final regulations to im-11 plement section 569C(b) of the Federal Food, Drug, and 12 Cosmetic Act, as added by this section. 13 SEC. 205. ENSURING COVERAGE FOR CLINICAL TRIALS 14 UNDER EXISTING STANDARD OF CARE. 15 (a) R EVISION TO DEFINITION OF APPROVED CLIN- 16 ICAL TRIAL IN INDIVIDUAL AND GROUP MARKET .\u2014 17 (1) I N GENERAL .\u2014Subsection (d)(1) of the first 18 section 2709 of the Public Health Service Act (42 19 U.S.C. 300gg-8) (relating to coverage for individ- 20 uals participating in approved clinical trials) is 21 amended by adding at the end the following new 22 subparagraph: 23 ''(D) The study or investigation is ap- 24 proved or funded (which may include funding 25 VerDate Nov 24 2008 15:17 by the Patient 1 Centered Outcomes Research Institute estab- 2 lished under section 1181 of the Social Security 3 Act.''. 4 (2) E FFECTIVE DATE .\u2014The amendment made 5 by this paragraph shall apply with respect to plan 6 years beginning on or after January 1, 2022. 7 (b) M EDICARE COVERAGE OF ROUTINE COSTS ASSO- 8 CIATED WITHCERTAIN CLINICAL TRIALS .\u2014 9 (1) I N GENERAL .\u2014Section 1862(m)(2) of the 10 Social Security Act (42 U.S.C.1395y(m)(2)) is 11 amended, in the matter preceding subparagraph (A), 12 by inserting ''(including a trial funded by the Pa- 13 tient Centered Outcomes Research Institute estab- 14 lished under section 1181)'' after ''means a trial''. 15 (2) E FFECTIVE DATE .\u2014The amendment made 16 by this paragraph shall apply with respect to items 17 and services furnished on or after the date of the en- 18 actment of this Act. 19 VerDate Nov 24 2008 AND DRUG 1 ADMINISTRATION 2 SEC. 301. REPORT ON COLLABORATION AND ALIGNMENT IN 3 REGULATING DIGITAL HEALTH TECH- 4 NOLOGIES. 5 (a) I NGENERAL .\u2014Not later than 1 year after the 6 date of enactment of this Act, the Secretary of Health and 7 Human Services, acting through the Commissioner of 8 Food and Drugs, shall submit a report to the Congress 9 on the efforts to ensure collaboration and alignment across 10 the centers and offices of the Food and Drug Administra-11 tion with respect to the regulation of digital health tech-12 nologies. 13 (b) C ONTENTS .\u2014 The report under subsection (a) 14 shall include a description of the following: 15 (1) How the Commissioner of Food and Drugs 16 and the heads of the centers and offices of the Food 17 and Drug Administration collaborate in regulating 18 digital health technologies, including recommenda- 19 tions with respect to\u2014 20 (A) the use of digital endpoints for regu- 21 latory review, including the validation and qual- 22 ification of digital endpoints and digital bio- 23 markers; 24 (B) the acceptance of decentralized trials; 25 VerDate Nov 24 2008 use of digital health technologies in 1 patient-focused development of products; and 2 (D) the use and validation of digital health 3 technology tools; 4 (2) How the Food and Drug Administration co- 5 ordinates with foreign regulators to ensure harmoni- 6 zation on the regulation and use of digital health 7 technologies. 8 (c) D EFINITION .\u2014In this section, the term ''digital 9 health technologies'' includes those technologies in health 10 care or society that help deliver or provide access to health 11 care products and services such as hardware (for example, 12 wearable sensors, virtual reality headsets, and digitally-en-13 abled drug delivery devices), advanced analytics (for exam-14 ple, artificial intelligence, machine learning, and sophisti-15 cated computation), cloud services (for example, storage, 16 computing, and data processing), and software (for exam-17 ple, mobile medical applications, and software as a medical 18 device). 19 SEC. 302. GRANTS FOR NOVEL TRIAL DESIGNS AND OTHER 20 INNOVATIONS IN DRUG DEVELOPMENT. 21 (a) I NGENERAL .\u2014The Secretary of Health and 22 Human Services, acting through the Commissioner of 23 Food and Drugs, shall award grants for\u2014 24 VerDate Nov 24 2008 incorporating complex adaptive and other 1 novel trial designs into clinical protocols and applica- 2 tions for drugs pursuant to an exemption for inves- 3 tigational use under section 505(i) of the Federal 4 Food, Drug, and Cosmetic Act (21 U.S.C. 355(i)) or 5 section 351(a) of the Public Health Service Act (42 6 U.S.C. 262(a)); and 7 (2) the collection of patient experience data 8 with respect to drugs and the use of such data and 9 related information in drug development. 10 (b) P RIORITIZATION .\u2014In awarding grants under this 11 section, the Secretary shall prioritize the incorporation of 12 digital health technologies and real world evidence in drug 13 development. 14 (c) D EFINITIONS .\u2014In this section: 15 (1) The term ''digital health technologies'' has 16 the meaning given to such term in section 301. 17 (2) The term ''patient experience data'' has the 18 meaning given to such term by section 569C(d) of 19 the Federal Food, Drug, and Cosmetic Act, as re- 20 designated by section 204 of this Act. 21 (3) The term ''real world evidence'' has the 22 meaning given to that term in section 505F of the 23 Federal Food, Drug, and Cosmetic Act (21 U.S.C. 24 355g). 25 VerDate Nov 24 OF APPROPRIATIONS .\u2014To carry 1 out this section, there is authorized to be appropriated 2 $25,000,000 for each of fiscal years 2022 through 2024. 3 SEC. 303. FDA CELL AND GENE THERAPY. 4 Not later than 1 year after the date of enactment 5 of this Act, the Secretary of Health and Human Services, 6 acting through the Commissioner of Food and Drugs, 7 shall submit a report to the Congress on the following: 8 (1) The foreseeable challenges to the Food and 9 Drug Administration with respect to cell and gene 10 therapies during the next ten years. 11 (2) How the Food and Drug Administration 12 will address these challenges. 13 (3) The additional resources and authorities the 14 Food and Drug Administration needs to address 15 these challenges. 16 (4) The current state of cell and gene therapies 17 regulation by the Food and Drug Administration, in- 18 cluding\u2014 19 (A) the amount and nature of the submis- 20 sions filed with the Food and Drug Administra- 21 tion; 22 (B) the status of such applications in the 23 review process; and 24 VerDate Nov 24 2008 the therapeutic areas intended to be 1 addressed by the products that are subject to 2 such applications. 3 SEC. 304. INCREASING USE OF REAL WORLD EVIDENCE. 4 (a) G UIDANCE .\u2014 5 (1) I SSUANCE .\u2014Not later than 6 months after 6 the date of enactment of this Act, the Secretary of 7 Health and Human Services (in this section referred 8 to as the ''Secretary'') shall issue guidance on the 9 use of real world evidence in evaluating the safety 10 and effectiveness of breakthrough devices (developed 11 pursuant to section 515B of the Federal Food, 12 Drug, and Cosmetic Act (21 U.S.C. 360e-3)) and 13 breakthrough drugs subsequent to the approval or li- 14 censing of such drugs pursuant to subsection (a), 15 (b), or (c) of section 506 of the Federal Food, Drug, 16 and Cosmetic Act (21 U.S.C. 356) as a break- 17 through therapy, a fast track product, or a product 18 considered for accelerated approval. 19 (2) C ONSIDERATIONS .\u2014The guidance under 20 paragraph (1) shall take into consideration each of 21 the following: 22 (A) Special and underrepresented popu- 23 lations. 24 Nov 24 endpoints and outcomes 1 measures. 2 (C) Data quality standards. 3 (D) Data transparency requirements. 4 (E) Study design considerations. 5 (b) I DENTIFICATION AND IMPLEMENTATION OF AP- 6 PROACHES .\u2014 7 (1) I DENTIFICATION .\u2014Consistent with the 8 framework established under 505F of the Federal 9 Food, Drug, and Cosmetic Act (21 U.S.C. 355g), 10 the Secretary of Health and Human Services shall, 11 by not later than 1 year after the date of enactment 12 of this Act\u2014 13 (A) identify consistent, clear approaches 14 for the Department of Health and Human 15 Services to use real world evidence (as defined 16 in such section 505F)\u2014 17 (i) in conducting and supporting re- 18 search; and 19 (ii) in regulating, purchasing, and 20 supporting the purchase of health care 21 products and services; 22 (B) include in such approaches rec- 23 ommendations for any additional statutory au- 24 thorities needed; 25 Nov 24 such approaches in the Federal 1 Register; and 2 (D) submit a report to the Congress on 3 such approaches. 4 (2) I MPLEMENTATION .\u2014Upon publication 5 under paragraph (1) of the approaches identified 6 pursuant to such paragraph, consistent with the au- 7 thorities vested in the Department of Health and 8 Human Services by other provisions of law, the Sec- 9 retary take such actions as may be appropriate to 10 implement the approaches identified pursuant to 11 paragraph (1). 12 (c) R EALWORLD EVIDENCE TASKFORCE .\u2014 13 (1) E STABLISHMENT .\u2014The Secretary shall es- 14 tablish a permanent task force, to be known as the 15 Real World Evidence Task Force (in this subsection 16 referred to as the ''Task Force'') to coordinate the 17 programs and activities of the Department of Health 18 and Human Services with regard to the collection 19 and use of real world evidence. 20 (2) M EMBERSHIP .\u2014The members of the Task 21 Force shall include the following: 22 (A) The Secretary (or the Secretary's des- 23 ignee), who shall serve as the Chair of the Task 24 Force. 25 VerDate Nov 24 2008 15:17 The Administrator of the Centers for 1 Medicare & Medicaid Services (or the Adminis- 2 trator's designee). 3 (C) The Commissioner of Food and Drugs 4 (or the Commissioner's designee). 5 (D) The Director of the National Insti- 6 tutes of Health (or the Director's designee). 7 (E) Such additional Federal officials (or 8 their designees) as the Secretary determines ap- 9 propriate. 10 (F) Private sector representatives, includ- 11 ing patient group representatives, to be ap- 12 pointed by the Secretary. 13 (3) R ECOMMENDATIONS .\u2014In carrying para- 14 graph (1), the Task Force shall\u2014 15 (A) develop and periodically update rec- 16 ommendations on ways to encourage patients 17 to\u2014 18 (i) engage in the generation of real 19 world evidence; and 20 (ii) participate in postapproval clinical 21 trials for the collection of real world evi- 22 dence; and 23 (B) not later than 2 years after the date 24 of enactment of this Act, and every 2 years 25 VerDate Nov 24 2008 15:17 submit a report to the Congress on 1 such recommendations. 2 SEC. 305. IMPROVING FDA-CMS COMMUNICATION REGARD-3 ING TRANSFORMATIVE NEW THERAPIES. 4 (a) I NGENERAL .\u2014Upon the designation of a product 5 as a breakthrough therapy, a fast track product, or a 6 product eligible for accelerated approval under subsection 7 (a), (b), or (c), respectively, of section 506 of the Federal 8 Food, Drug, and Cosmetic Act (21 U.S.C. 356), the Com-9 missioner of Food and Drugs and the Administrator of 10 the Centers for Medicare & Medicaid Services shall\u2014 11 (1) maintain communication with each other re- 12 garding approval and coverage decisions with respect 13 to such product; and 14 (2) share such information with each other as 15 may be appropriate to inform and coordinate such 16 decisions. 17 (b) S EPARATE AND DISTINCT .\u2014In approving or des- 18 ignating a product described in subsection (a), the Com-19 missioner of Food and Drugs and the Administrator of 20 the Centers for Medicare & Medicaid Services shall ensure 21 that the process for approval or designation remains sepa-22 rate and distinct. 23 VerDate Nov 24 2008 OF ADDITIONAL INTERCENTER 1 INSTITUTES AT THE FOOD AND DRUG ADMIN- 2 ISTRATION. 3 (a) E STABLISHMENT .\u2014Subsection (c) of section 4 1014 of the Federal Food, Drug, and Cosmetic Act (21 5 U.S.C. 399g(c)) is amended to read as follows: 6 ''(c) T IMING .\u2014Not later than the date that is one 7 year after the date of enactment of the Cures 2.0 Act or 8 the end of the coronavirus disease 2019 (COVID-19) pan-9 demic public health emergency under section 319 of the 10 Public Health Service Act, whichever is later, the Sec-11 retary shall establish, in accordance with this section, at 12 least two additional Institutes under subsection (a).''. 13 (b) C RITERIA .\u2014In establishing the focus of the two 14 Institutes referenced in the amendment made by sub-15 section (a), the Secretary of Health and Human Services 16 shall ensure the following: 17 (1) One of the Institutes focuses on a group of 18 diseases meeting the following criteria: 19 (A) Negatively affects at least one major 20 body system. 21 (B) Represents a major disease burden in 22 the United States. 23 (C) Represents a leading cause of mor- 24 tality or disability in the United States. 25 VerDate Nov 24 2008 15:17 According to the National Institutes of 1 Health, affects at least an estimated 2 50,000,000 Americans each year. 3 (E) Contributes to increasing health care 4 (personal, familial, private sector, and govern- 5 mental) expenditures and impacts the United 6 States economy as a whole. 7 (F) For which the SARS-CoV-2 virus ex- 8 acerbates symptoms or causes serious complica- 9 tions. 10 (G) For which medical products are ap- 11 proved by the Food and Drug Administration 12 at a much lower rate than products for other 13 disease areas, including in abbreviated path- 14 ways. 15 (2) One of the Institutes focuses on a group of 16 diseases meeting the following criteria: 17 (A) Affects, individually, fewer than 18 200,000 people in the United States. 19 (B) Over 90 percent of such diseases have 20 no therapy approved by the Food and Drug Ad- 21 ministration. 22 (C) Affects, in total, over 30,000,000 23 Americans. 24 VerDate Nov 24 2008 Over 50 percent of patients are chil- 1 dren. 2 (c) R EPORT ON INTERCENTER INSTITUTES .\u2014Not 3 later than 2 years after the date of enactment of this Act, 4 and annually thereafter, the Secretary of Health and 5 Human Services, acting through the Commissioner of 6 Food and Drugs, shall submit a report to the Committee 7 on Energy and Commerce of the House of Representatives 8 and the Committee on Health, Education, Labor, and 9 Pensions of the Senate on the activities of the Institutes 10 established pursuant to this section. 11 SEC. 307. ACCELERATING TIMELINE FOR BREAKTHROUGH 12 AND RMAT DESIGNATIONS. 13 (a) B REAKTHROUGH THERAPIES .\u2014Section 14 506(a)(2) of the Federal Food, Drug, and Cosmetic Act 15 (21 U.S.C. 356(a)(2)) is amended by striking ''A request 16 for the designation may be made concurrently with, or at 17 any time after, the submission of an application for the 18 investigation of the drug under section 505(i) or section 19 351(a)(3) of the Public Health Service Act'' and inserting 20 ''A request for the designation may be made at any point 21 before or after submission of an application for approval 22 of the drug under section 505(b) of this Act or licensure 23 of the drug under section 351(a)(2) of the Public Health 24 Service Act and shall include clinical evidence, including 25 VerDate Nov 24 2008 15:17 clinical evidence from clinical trials conducted 1 outside of the United States''. 2 (b) R EGENERATIVE ADVANCED THERAPIES .\u2014Sec- 3 tion 506(g)(3) of the Federal Food, Drug, and Cosmetic 4 Act (21 U.S.C. 356(g)(3)) is amended by striking ''con-5 currently with, or at any time after, submission of an ap-6 plication for the investigation of the drug under section 7 505(i) of this Act or section 351(a)(3) of the Public 8 Health Service Act'' and inserting ''at any point before 9 or after submission of an application for approval of the 10 drug under section 505(b) of this Act or licensure of the 11 drug under section 351(a)(2) of the Public Health Service 12 Act and shall include clinical evidence, including prelimi-13 nary clinical evidence from clinical trials conducted outside 14 of the United States''. 15 SEC. 308. GUIDANCE REGARDING DEVELOPMENT AND SUB-16 MISSION OF CHEMISTRY, MANUFACTURING, 17 AND CONTROLS INFORMATION FOR EXPE- 18 DITED APPROVAL. 19 (a) I NGENERAL .\u2014The Secretary of Health and 20 Human Services shall\u2014 21 (1) not later than 6 months after the date of 22 enactment of this Act, issue draft revised guidance 23 to provide clarity regarding the development and 24 submission of chemistry, manufacturing, and con- 25 VerDate Nov 24 2008 15:17 purposes of subsections (a), 1 (b), (c), and (g) of section 506 of the Federal Food, 2 Drug, and Cosmetic Act (21 U.S.C. 356; relating to 3 breakthrough therapies, fast track products, acceler- 4 ated approval, and regenerative advanced therapies); 5 and 6 (2) not later than 90 days after the close of a 7 period of public comment on such draft guidance, fi- 8 nalize the guidance. 9 (b) C ONTENTS .\u2014The guidance under subsection (a) 10 shall address\u2014 11 (1) how the Food and Drug Administration will 12 determine how, and by when, chemistry, manufac- 13 turing, and controls information is required to be 14 submitted throughout development and during the 15 pre- and post-approval phases, taking into consider- 16 ation\u2014 17 (A) how such determinations will reflect 18 the risks and benefits of such information given 19 the seriousness or life-threatening nature of the 20 disease the product is intended to diagnose, 21 cure, mitigate, treat, or prevent; 22 (B) the phase and expedited nature of de- 23 velopment; and 24 VerDate Nov 24 the availability of relevant data and in- 1 formation from nonclinical and clinical studies, 2 product applications, and post-approval over- 3 sight; and 4 (2) how the Food and Drug Administration will 5 provide ongoing advice and opportunities for spon- 6 sors to interact with the Food and Drug Administra- 7 tion on, and how the Food and Drug Administration 8 will facilitate, the submission of chemistry, manufac- 9 turing, and controls information throughout the life 10 cycle of the product. 11 SEC. 309. POST-APPROVAL STUDY REQUIREMENTS FOR AC-12 CELERATED APPROVAL. 13 Section 506(c)(2)(A) of the Federal Food, Drug, and 14 Cosmetic Act (21 U.S.C. 356(c)(2)(A)) is amended after 15 ''studies'' by inserting '', or otherwise submit evidence 16 based on analyses of data in clinical care data repositories, 17 patient registries, or other sources of real world evi-18 dence,''. 19 SEC. 310. RECOMMENDATIONS TO DECENTRALIZE CLIN-20 ICAL TRIALS. 21 (a) I NGENERAL .\u2014Not later than the end of fiscal 22 year 2022, the Secretary of Health and Human Services, 23 acting through the Commissioner of Food and Drugs, 24 shall convene a meeting of covered representatives to rec-25 VerDate Nov 24 2008 innovative approaches and in-1 centives to adopt decentralized clinical trials. 2 (b) D EFINITIONS .\u2014In this section: 3 (1) C OVERED REPRESENTATIVE .\u2014The term 4 ''covered representative'' means a representative of 5 the following: 6 (A) Sponsors of an application for approval 7 of a drug under section 505 of the Federal 8 Food, Drug, and Cosmetic Act (21 U.S.C. 9 355). 10 (B) A manufacturer of a device (as defined 11 in section 201 of the Federal Food, Drug, and 12 Cosmetic Act (21 U.S.C. 321)). 13 (C) Clinical research organizations. 14 (D) The technology community. 15 (E) The patient community. 16 (2) D ECENTRALIZED CLINICAL TRIAL .\u2014The 17 term ''decentralized clinical trial'' means a clinical 18 trial method that includes the use of telemedicine or 19 digital technologies to allow for the remote collection 20 of clinical trial data from subjects, including in the 21 home or office setting. 22 VerDate Nov 24 2008 15:17 MEDI-1 CARE & MEDICAID SERVICES 2 Subtitle A 3 SEC. 401. GAO STUDY AND REPORT. 4 Not later than one year after the date of the enact- 5 ment of this Act, the Comptroller General of the United 6 States shall submit to Congress a report on recommenda-7 tions for administrative actions that may be taken by the 8 Secretary of Health and Human Services (as well as rec-9 ommendations for legislative changes needed) to\u2014 10 (1) enhance coverage and reimbursement ap- 11 proaches under the Medicare program under title 12 XVIII of the Social Security Act for innovative tech- 13 nologies that increase access to health care, improve 14 health care quality, decrease expenditures under 15 such program, or otherwise improve the Medicare 16 program or health care for beneficiaries under such 17 program; and 18 (2) better harmonize and integrate the oper- 19 ating structure of the Medicare program (and the 20 Centers for Medicare & Medicaid Services) to im- 21 prove interagency collaboration and communication. 22 VerDate Nov 24 2008 15:17 INCREASE ACCESS TO TELE-1 HEALTH UNDER MEDICAID AND CHILDREN'S 2 HEALTH INSURANCE PROGRAM. 3 (a) G UIDANCE .\u2014Not later than one year after the 4 date of the enactment of this Act, the Secretary of Health 5 and Human Services shall issue and disseminate guidance 6 to States to clarify strategies to overcome existing barriers 7 and increase access to telehealth under the Medicaid pro-8 gram under title XIX of the Social Security Act (42 9 U.S.C. 1396 et seq.) and the Children's Health Insurance 10 Program under title XXI of such Act (42 U.S.C. 1397aa 11 et seq.). Such guidance shall include technical assistance 12 and best practices regarding\u2014 13 (1) existing strategies States can use to inte- 14 grate telehealth and other virtual health care serv- 15 ices into value-based health care models; and 16 (2) examples of States that have used waivers 17 under the Medicaid program to test expanded access 18 to telehealth, including during the emergency period 19 described in section 1135(g)(1)(B) of the Social Se- 20 curity Act (42 U.S.C. 1320b-5(g)(1)(B)). 21 (b) S TUDIES .\u2014 22 (1) T ELEHEALTH IMPACT ON HEALTH CARE 23 ACCESS .\u2014Not later than one year after the date of 24 the enactment of this Act, the Medicaid and CHIP 25 Payment and Access Commission shall conduct a 26 VerDate Nov 24 2008 15:17 with respect to a minimum of 10 States 1 across geographic regions of the United States, and 2 submit to Congress a report, on the impact of tele- 3 health on health care access, utilization, cost, and 4 outcomes, broken down by race, ethnicity, sex, age, 5 disability status, and zip code. Such report shall\u2014 6 (A) evaluate cost, access, utilization, out- 7 comes, and patient experience data from across 8 the health care field, including States, Medicaid 9 managed care organizations, provider organiza- 10 tions, and other organizations that provide or 11 pay for telehealth under the Medicaid program 12 and Children's Health Insurance Program; 13 (B) identify barriers and potential solu- 14 tions to provider entry and participation in tele- 15 health that States are experiencing, as well as 16 barriers to providing telehealth across State 17 lines, including during times of public health 18 crisis or public health emergency; 19 (C) determine the frequency at which out- 20 of-State telehealth is provided to patients en- 21 rolled in the Medicaid program and the poten- 22 tial impact on access to telehealth if State Med- 23 icaid policies were more aligned; and 24 24 identify and evaluate opportunities for 1 more alignment among such policies to promote 2 access to telehealth across all States, State 3 Medicaid plans under title XIX of the Social 4 Security Act (42 U.S.C. 1396 et seq.), State 5 child health plans under title XXI of such Act 6 (42 U.S.C. 1397aa et seq.), and Medicaid man- 7 aged care organizations, including the potential 8 for regional compacts or reciprocity agreements. 9 (2) F EDERAL AGENCY TELEHEALTH COLLABO - 10 RATION .\u2014Not later than 1 year after the date of the 11 enactment of this Act, the Comptroller General of 12 the United States shall conduct a study and submit 13 to Congress a report evaluating collaboration be- 14 tween Federal agencies with respect to telehealth 15 services furnished under the Medicaid or CHIP pro- 16 gram to individuals under the age of 18, including 17 such services furnished to such individuals in early 18 care and education settings. Such report shall in- 19 clude recommendations on\u2014 20 (A) opportunities for Federal agencies to 21 improve collaboration with respect to such tele- 22 health services; and 23 (B) opportunities for collaboration between 24 Federal agencies to expand telehealth access to 25 VerDate Nov 24 2008 individuals enrolled under the Medicaid or 1 CHIP program, including in early care and 2 education settings. 3 SEC. 403. EXTENDING MEDICARE TELEHEALTH FLEXIBILI-4 TIES. 5 (a) E XPANDING ACCESS TO TELEHEALTH SERV- 6 ICES.\u2014 7 (1) I N GENERAL .\u2014Section 1834(m)(4)(C) of 8 the Social Security Act (42 U.S.C. 1395m(m)(4)(C)) 9 is amended by adding at the end the following new 10 clause: 11 ''(iii) E XPANDING ACCESS TO TELE - 12 HEALTH SERVICES .\u2014With respect to tele- 13 health services furnished beginning on the 14 first day after the end of the emergency 15 period described in section 1135(g)(1)(B) 16 of this clause, the term 'originating site' 17 means any site at which the eligible tele- 18 health individual is located at the time the 19 service is furnished via a telecommuni- 20 cations system, including the home of an 21 individual.''. 22 (2) C ONFORMING AMENDMENTS .\u2014Such section 23 is amended\u2014 24 (A) in paragraph (2)(B)\u2014 25 VerDate Nov 24 clause (i), in the matter pre- 1 ceding subclause (I), by striking ''clause 2 (ii)'' and inserting ''clauses (ii) and (iii)''; 3 and 4 (ii) by adding at the end the following 5 new clause: 6 ''(iii) N O FACILITY FEE FOR NEW 7 SITES .\u2014With respect to telehealth services 8 furnished on or after the date of enact- 9 ment of this clause, a facility fee shall only 10 be paid under this subparagraph to an 11 originating site that is described in para- 12 graph (4)(C)(ii) (other than subclause (X) 13 of such paragraph).''; 14 (B) in paragraph (4)(C)\u2014 15 (i) in clause (i), in the matter pre- 16 ceding subclause (I), by inserting ''and 17 clause (iii)'' after ''and (7)''; and 18 (ii) in clause (ii)(X), by inserting 19 ''prior to the first day after the end of the 20 emergency period described in section 21 1135(g)(1)(B)'' before the period; 22 (C) in paragraph (5), by inserting ''and 23 prior to the first day after the end of the emer- 24 VerDate Nov 24 2008 after ''January 1, 2019,''; 2 (D) in paragraph (6)(A), by inserting ''and 3 prior to the first day after the end of the emer- 4 gency period described in section 5 1135(g)(1)(B),'' after ''January 1, 2019,''; and 6 (E) in paragraph (7), by adding at the end 7 the following new subparagraph: 8 ''(C) S UNSET .\u2014The provisions of this 9 paragraph shall not apply with respect to serv- 10 ices furnished on or after the first day after the 11 end of the emergency period described in sec- 12 tion 1135(g)(1)(B).''. 13 (b) E XPANDING PRACTITIONERS ELIGIBLE TOFUR- 14 NISH TELEHEALTH SERVICES .\u2014Section 1834(m) of the 15 Social Security Act (42 U.S.C. 1395m(m)) is amended\u2014 16 (1) in paragraph (1), by striking ''(described in 17 section 1842(b)(18)(C))'' and inserting ''(defined in 18 paragraph (4)(E))''; and 19 (2) in paragraph (4)(E)\u2014 20 (A) by striking '' PRACTITIONER .\u2014The 21 term'' and inserting ''P RACTITIONER .\u2014 22 ''(A) I N GENERAL .\u2014Subject to subpara- 23 graph (B), the term''; and 24 Nov 24 2008 adding at the end the following new 1 subparagraph: 2 ''(B) E XPANSION .\u2014The Secretary, after 3 consulting with stakeholders regarding services 4 that are clinically appropriate, may expand the 5 types of practitioners who may furnish tele- 6 health services to include any health care pro- 7 fessional that is eligible to bill the program 8 under this title for their professional services.''. 9 (c) R ETENTION OF ADDITIONAL SERVICES AND SUB- 10 REGULATORY PROCESS FOR MODIFICATIONS FOLLOWING 11 EMERGENCY PERIOD .\u2014Section 1834(m)(4)(F) of the So- 12 cial Security Act (42 U.S.C. 1395m(m)(4)(F)) is amend-13 ed\u2014 14 (1) in clause (i), by inserting ''and clause (iii)'' 15 after ''paragraph (8)''; 16 (2) in clause (ii), by striking ''The Secretary'' 17 and inserting ''Subject to clause (iii), the Sec- 18 retary''; and 19 (3) by adding at the end the following new 20 clause: 21 ''(iii) R ETENTION OF ADDITIONAL 22 SERVICES AND SUBREGULATORY PROCESS 23 FOR MODIFICATIONS FOLLOWING EMER - 24 GENCY PERIOD .\u2014With respect to tele- services furnished after the last day 1 of the emergency period described in sec- 2 tion 1135(g)(1)(B), the Secretary may\u2014 3 ''(I) retain as appropriate the ex- 4 panded list of telehealth services spec- 5 ified in clause (i) pursuant to the 6 waiver authority under section 7 1135(b)(8) during such emergency pe- 8 riod; and 9 ''(II) retain the subregulatory 10 process used to modify the services in- 11 cluded on the list of such telehealth 12 services pursuant to clause (ii) during 13 such emergency period.''. 14 (d) E NHANCING TELEHEALTH SERVICES FOR FED- 15 ERALLY QUALIFIED HEALTH CENTERS AND RURAL 16 HEALTH CLINICS .\u2014Section 1834(m)(8) of the Social Se- 17 curity Act (42 U.S.C. 1395m(m)(8)) is amended\u2014 18 (1) in the paragraph heading by inserting '' AND 19 AFTER '' after '' DURING ''; 20 (2) in subparagraph (A), in the matter pre- 21 ceding clause (i), by inserting ''and after'' after 22 ''During''; and 23 (3) in the first sentence of subparagraph (B)(i), 24 by inserting ''and after'' after CARE.\u2014Section So- 3 cial Security Act (42 U.S.C. 1395f(a)(7)(D)(i)(II)) is 4 amended by inserting ''and after such emergency period 5 as clinically appropriate'' after ''1135(g)(1)(B)''. 6 (f) U SE - 8 MENTS FOR HOME DIALYSIS .\u2014Clause (iii) of section 9 1881(b)(3)(B) of the Social Security Act (42 U.S.C. 10 1395rr(b)(3)(B)) is amended\u2014 11 (1) by moving such clause 4 ems to the left; 12 and 13 (2) by inserting ''and after such emergency pe- 14 riod as clinically appropriate'' before the period. 15 (g) I MPLEMENTATION .\u2014Notwithstanding any provi- 16 sion of law, the Secretary may implement the provisions 17 of, and amendments made by, this section by interim final 18 rule, program instruction, or otherwise. 19 SEC. 404. COVERAGE AND PAYMENT FOR BREAKTHROUGH 20 DEVICES UNDER THE MEDICARE PROGRAM. 21 (a) I NGENERAL .\u2014Part E of title XVIII of the Social 22 Security Act (42 U.S.C. 1395x et seq.) is amended by add-23 ing at the end the following new section: 24 VerDate Nov 24 2008 ''(a) B REAKTHROUGH DEVICES .\u2014For purposes of 2 this section, the term 'breakthrough device' means a med-3 ical device that is a device (as defined in section 201 of 4 the Federal Food, Drug, and Cosmetic Act) and that is\u2014 5 ''(1) provided with review priority by the Sec- 6 retary under subsection (d)(5) of section 515 of such 7 Act; and 8 ''(2) approved or cleared pursuant to section 9 510(k), 513(f), or 515 of such Act for use in treat- 10 ing an indication on or after March 15, 2021. 11 Such term also includes a breakthrough device that is a 12 specified breakthrough device (as defined in subsection 13 (e)(1)(B)) approved or cleared pursuant to section 510(k), 14 513(f), or 515 of such Act for use in treating an indication 15 on or after March 15, 2021. 16 ''(b) C OVERAGE .\u2014 17 ''(1) T RANSITIONAL COVERAGE .\u2014 18 ''(A) I N GENERAL .\u2014During the transi- 19 tional coverage period (as defined in subpara- 20 graph (B)) a breakthrough device shall be\u2014 21 ''(i) deemed to be reasonable and nec- 22 essary for purposes of section 23 1862(a)(1)(A); 24 ''(ii) deemed to be approved for an ad- 25 ditional payment under section 26 VerDate Nov 24 2008 than with respect to 1 the cost criterion under clause (ii)(I) of 2 such section); 3 ''(iii) deemed to be approved for pass- 4 through payment under section 1833(t)(6) 5 and section 1833(i) (other than with re- 6 spect to the cost criterion under section 7 1833(t)(6)(A)(iv)); and 8 ''(iv) insofar as such breakthrough de- 9 vice may be furnished in a setting for 10 which payment is made under an applica- 11 ble payment system described in subpara- 12 graphs (D) through (I) of subsection 13 (c)(4), deemed eligible for an additional 14 payment or payment adjustment, as the 15 case may be, pursuant to subsection (d)(3) 16 when furnished in a setting for which pay- 17 ment is made under such an applicable 18 payment system during such transitional 19 coverage period. 20 ''(B) T RANSITIONAL COVERAGE PERIOD 21 DEFINED .\u2014As used in this section, the term 22 'transitional coverage period' means, with re- 23 spect to a breakthrough device, the period 24 that\u2014 25 VerDate Nov 24 2008 on the date of the approval 1 under section 515 of the Federal Food, 2 Drug, and Cosmetic Act or of the clear- 3 ance under section 510(k) of such Act, as 4 applicable, of such device by the Secretary 5 for the indication described in subsection 6 (a)(1); and 7 ''(ii) ends on the last day of the 4- 8 year period that begins on the date that 9 the Secretary, pursuant to subsection 10 (c)(2), updates the relevant applicable pay- 11 ment system (as defined in subsection 12 (c)(4)) to recognize the unique temporary 13 or permanent code or codes assigned under 14 subsection (c)(1) to such breakthrough de- 15 vice, except as provided in subsections 16 (d)(1)(B) and (d)(2)(B). 17 ''(C) D ATA USED TO MEET THE NTAP AND 18 PASS -THROUGH COST CRITERIA .\u2014In deter- 19 mining whether a breakthrough device qualifies 20 for an additional payment under section 21 1886(d)(5)(K) or for pass-through payment 22 under section 1833(t)(6) or section 1833(i), the 23 Secretary shall use the most recently available 24 data and information on the costs of such 25 VerDate Nov 24 2008 15:17 which may include list 1 prices and invoice prices charged for such 2 breakthrough device. 3 ''(2) P ROCESS FOR REGULAR COVERAGE .\u2014For 4 purposes of the application of section 1862(a)(1)(A) 5 to a breakthrough device furnished after the transi- 6 tional coverage period (as defined in paragraph 7 (1)(B)) for such device, the Secretary shall establish 8 a process for the coverage of such breakthrough de- 9 vices under this title after such period as follows: 10 ''(A) I DENTIFICATION OF ADDITIONAL EVI - 11 DENCE .\u2014 12 ''(i) I N GENERAL .\u2014With respect to a 13 breakthrough device, not later than 1 year 14 after the date of the approval of such de- 15 vice under section 515 of the Federal 16 Food, Drug, and Cosmetic Act or of the 17 clearance of such device under section 18 510(k) of such Act, as applicable, the Sec- 19 retary shall identify whether any additional 20 data or evidence is required with respect to 21 any indications for such device for pur- 22 poses of the application of such section 23 1862(a)(1)(A) to such device for such indi- 24 cations. 25 Nov 24 DATA RE - 1 QUESTS .\u2014In carrying out clause (i) with 2 respect to a breakthrough device, the Sec- 3 retary shall ensure that data or evidence 4 identified\u2014 5 ''(I) does not duplicate data re- 6 quired to be collected by the Food and 7 Drug Administration with respect to 8 such breakthrough device; 9 ''(II) minimizes the administra- 10 tive burdens of data collection and re- 11 porting on providers of services, sup- 12 pliers, and manufacturers of break- 13 through devices; and 14 ''(III) is not otherwise unneces- 15 sary or redundant. 16 ''(B) P ROPOSAL FOR COVERAGE AFTER 17 THE TRANSITIONAL COVERAGE PERIOD .\u2014Not 18 later than 2 years after the date of the approval 19 or clearance of a breakthrough device by the 20 Food and Drug Administration, the Secretary 21 shall develop a proposal for coverage under this 22 title of such breakthrough device for such indi- 23 cations as the Secretary determines to be ap- 24 propriate, based on the data and evidence col- 25 VerDate Nov 24 2008 (A), for such devices 1 furnished after the transitional coverage period 2 under paragraph (1) for such device. If the Sec- 3 retary does not, on a date that is before the end 4 of such two-year period, take action to modify 5 the indications for which coverage of a break- 6 through device may be provided under this title 7 after such period, for purposes of section 8 1862(a)(1)(A) coverage under this title of such 9 breakthrough device shall be made for all indi- 10 cations for which such device is approved under 11 section 515 of the Federal Food, Drug, and 12 Cosmetic Act or cleared under section 510(k) of 13 such Act. 14 ''(3) R ULES OF CONSTRUCTION .\u2014Nothing in 15 this section shall be construed to\u2014 16 ''(A) affect the ability of the manufacturer 17 of a breakthrough device to seek approval for 18 pass-through payment status under section 19 1833(t)(6) or to seek approval for an additional 20 payment under section 1886(d)(5)(K) insofar 21 as such breakthrough device does not qualify 22 for transitional coverage under paragraph (1); 23 ''(B) affect the application and approval 24 process for pass-through payment status under 25 VerDate Nov 24 2008 for an additional payment 1 under section 1886(d)(5)(K) in the case of a 2 medical device that is not approved by the Food 3 and Drug Administration as a breakthrough de- 4 vice; or 5 ''(C) prohibit the Secretary from using ex- 6 isting authority under this title to suspend or 7 terminate coverage of a breakthrough device if 8 the Secretary, based on clinical evidence, deter- 9 mines that\u2014 10 ''(i) such breakthrough device offers 11 no clinical benefit to Medicare bene- 12 ficiaries; or 13 ''(ii) furnishing such breakthrough de- 14 vice to Medicare beneficiaries causes, or 15 may cause, serious harm to Medicare bene- 16 ficiaries. 17 ''(c) C ODING .\u2014 18 ''(1) P ROMPT ASSIGNMENT .\u2014Not later than 19 three months after the date of approval or clearance 20 of a breakthrough device by the Food and Drug Ad- 21 ministration, the Secretary shall assign a unique 22 temporary or permanent code or codes for purposes 23 of coverage and payment for such breakthrough de- 24 VerDate Nov 24 2008 applicable payment systems (de- 1 scribed in paragraph (4)). 2 ''(2) U PDATES .\u2014 3 ''(A) I PPS.\u2014The Secretary shall provide 4 for semiannual updates under the applicable 5 payment system described in paragraph (4)(A) 6 (relating to the inpatient hospital prospective 7 payment system) to recognize the code or codes 8 assigned under paragraph (1). 9 ''(B) O PPS.\u2014The Secretary shall provide 10 for quarterly updates under the applicable pay- 11 ment system described in paragraph (4)(B) (re- 12 lating to the outpatient hospital prospective 13 payment system) to recognize the code or codes 14 assigned under paragraph (1). 15 ''(C) O THER PAYMENT SYSTEMS .\u2014The 16 Secretary shall provide for semiannual or quar- 17 terly updates, as the case may be, under the ap- 18 plicable payment systems described in subpara- 19 graphs (C) through (L) of paragraph (4) to rec- 20 ognize the code or codes assigned under para- 21 graph (1). 22 ''(3) T RANSPARENCY .\u2014The process for the as- 23 signment of a code or codes under this subsection 24 VerDate Nov 24 2008 for public notice and a meaningful op- 1 portunity for public comment from affected parties. 2 ''(4) A PPLICABLE PAYMENT SYSTEMS DE - 3 SCRIBED .\u2014For purposes of this subsection, the term 4 'applicable payment systems' means\u2014 5 ''(A) with respect to inpatient hospital 6 services, the prospective payment system for in- 7 patient hospital services established under sec- 8 tion 1886(d); 9 ''(B) with respect to outpatient hospital 10 services, the prospective payment system for 11 covered OPD services established under section 12 1833(t); 13 ''(C) with respect to ambulatory surgical 14 center services, the fee schedule for such serv- 15 ices established under 1833(i); 16 ''(D) with respect to physicians' services, 17 the physician fee schedules established under 18 section 1848; 19 ''(E) with respect to covered items of dura- 20 ble medical equipment, the applicable fee sched- 21 ules established under section 1834; 22 ''(F) with respect to diagnostic laboratory 23 tests, the payment amounts under section 24 VerDate Nov 24 2008 15:17 the fee schedules establish under 1 section 1848, as the case may be; 2 ''(G) with respect to inpatient hospital 3 services furnished by rehabilitation facilities, 4 the prospective payment system established 5 under section 1886(j); 6 ''(H) with respect to inpatient hospital 7 services furnished by long-term care hospitals, 8 the prospective payment system under section 9 1886(m); 10 ''(I) with respect to inpatient hospital serv- 11 ices furnished by psychiatric hospitals and psy- 12 chiatric units, the prospective payment system 13 under section 1886(s); 14 ''(K) with respect to home health services, 15 the prospective payment system under section 16 1895; and 17 ''(L) with respect to items and services, or 18 a provider of services or supplier, not described 19 in subparagraphs (A) through (I), the payment 20 system established under this title for such 21 items and services when furnished by such pro- 22 vider of services or supplier. 23 ''(d) P AYMENT .\u2014 24 VerDate Nov 24 HOSPITAL PROSPECTIVE PAY - 1 MENT SYSTEM : DEEMED ELIGIBILITY FOR BREAK - 2 THROUGH PAYMENT .\u2014The Secretary shall deem 3 each breakthrough device as approved for an addi- 4 tional payment under section 1886(d)(5)(K) for the 5 4-year period that begins\u2014 6 ''(A) except as provided in subparagraph 7 (B), on the date that the Secretary, pursuant to 8 subsection (c)(2)(A), updates the payment sys- 9 tem under section 1886(d) to recognize the 10 unique temporary or permanent code or codes 11 assigned under subsection (c)(1) to such break- 12 through device; or 13 ''(B) in the case of a device that has not 14 received approval or clearance as a break- 15 through device by the Food and Drug Adminis- 16 tration before such payment system is updated 17 under subsection (c)(2)(A) to recognize the 18 unique temporary or permanent code or codes 19 assigned under subsection (c)(1) to such device, 20 on the date of such approval or clearance. 21 Nothing in this paragraph shall be construed to af- 22 fect the authority of the Secretary to use claims 23 data to establish new diagnosis or procedure codes 24 for breakthrough devices or to identify appropriate 25 VerDate Nov 24 2008 15:17 the assignment of 1 breakthrough devices under annual rulemaking to 2 carry out section 1886(d)(5)(K). 3 ''(2) O UTPATIENT PROSPECTIVE PAYMENT SYS - 4 TEM: DEEMED ELIGIBILITY FOR PASS -THROUGH 5 PAYMENT .\u2014The Secretary shall deem each break- 6 through device as approved for pass-through pay- 7 ment under section 1833(t)(6) (including for pur- 8 poses of section 1833(i)(2)(D)) during the 4-year pe- 9 riod that begins\u2014 10 ''(A) except as provided in subparagraph 11 (B), on the date that the Secretary, pursuant to 12 subsection (c)(2)(B), updates the payment sys- 13 tem under section 1833(t) to recognize the 14 unique temporary or permanent code or codes 15 assigned under subsection (c)(1) to such break- 16 through device; or 17 ''(B) in the case of a device that has not 18 received approval or clearance as a break- 19 through device by the Food and Drug Adminis- 20 tration before such payment system is updated 21 under subsection (c)(2)(B) to recognize the 22 unique temporary or permanent code or codes 23 assigned under subsection (c)(1) to such device, 24 on the date of such approval or clearance. 25 VerDate Nov 24 2008 15:17 this paragraph shall be construed to af- 1 fect the authority of the Secretary to use claims 2 data to establish new ambulatory payment classifica- 3 tion groups for breakthrough devices or to revise 4 such groups to take into account breakthrough de- 5 vices under annual rulemaking to carry out section 6 1833(t). 7 ''(3) O THER PAYMENT SYSTEMS .\u2014 8 ''(A) I N GENERAL .\u2014In the case of break- 9 through device that is furnished and for which 10 payment may be made under the payment sys- 11 tem established under section 1834, 1834A, 12 1848, 1886(j), 1886(m), 1886(s), or 1895 or 13 any other provision of this title (other than sec- 14 tions 1833(i), 1833(t), and 1886(d)), the Sec- 15 retary shall provide for an additional payment 16 for such breakthrough device under such appli- 17 cable payment system or an adjustment to such 18 applicable payment system, as the case may be. 19 The payment basis for such additional payment 20 or adjustment, as the case may be, shall equal 21 an amount that the Secretary determines covers 22 the costs of such breakthrough device. 23 ''(B) C OST INFORMATION .\u2014In determining 24 the costs of a breakthrough device for purposes 25 VerDate Nov 24 2008 15:17 additional payment or pay- 1 ment adjustment under subparagraph (A), the 2 Secretary shall use the most recently available 3 data and information on the costs of such 4 breakthrough device, which may include list 5 prices and invoice prices charged for such 6 breakthrough device. 7 ''(C) R ULE OF CONSTRUCTION .\u2014Nothing 8 in this paragraph shall be construed to affect 9 the authority of the Secretary to use claims 10 data to establish new or modify existing ambu- 11 latory payment classification groups, diagnosis- 12 related groups, level II HCPCS codes or such 13 other groups or codes as the Secretary may es- 14 tablish under the annual rulemaking authority 15 under the provisions referred to in subpara- 16 graph (A). 17 ''(D) C LINICAL DIAGNOSTIC LABORATORY 18 TESTS .\u2014An additional payment or payment ad- 19 justment under subparagraph (A) for a break- 20 through device under the applicable payment 21 system established in section 1834A may be in 22 the form of an increase to the amount deter- 23 mined for the breakthrough device using cross- 24 walking under section 1834A(c)(1)(A), an ex- 25 VerDate Nov 24 2008 the initial period of payment applica- 1 ble to advance diagnostic laboratory tests under 2 section 1834A(d)(1)(A), and in such other form 3 or manner as the Secretary determines reflects 4 the costs for such breakthrough device under 5 the relevant provisions of section 1834A. 6 ''(4) P AYMENT FOR BREAKTHROUGH DEVICES 7 AFTER THE TRANSITIONAL COVERAGE PERIOD .\u2014 8 Payment for a breakthrough device that is furnished 9 after the conclusion of the transitional coverage pe- 10 riod under subsection (b)(1) for such device shall be 11 made pursuant to the applicable payment system in- 12 volved, taking into account the additional evidence 13 and data collected under subsection (b)(2). 14 ''(e) S PECIAL RULES FOR CERTAIN BREAKTHROUGH 15 DEVICES .\u2014 16 ''(1) C OVERAGE OF SPECIFIED BREAKTHROUGH 17 DEVICES .\u2014 18 ''(A) I N GENERAL .\u2014Subject to the suc- 19 ceeding provisions of this subsection and not- 20 withstanding any other provision of law, the 21 Secretary shall provide for coverage and pay- 22 ment pursuant to this section of a specified 23 breakthrough device (as defined in subpara- 24 graph (B)). 25 VerDate Nov 24 2008 .\u2014In this section, the term 'specified 2 breakthrough device' means a breakthrough de- 3 vice with respect to which no Medicare benefit 4 category exists. 5 ''(2) P ERIOD OF TRANSITIONAL COVERAGE .\u2014 6 ''(A) I N GENERAL .\u2014Subject to subpara- 7 graph (C), the provisions of subsection (b)(1) 8 (relating to the transitional coverage period and 9 payment for breakthrough devices, including the 10 use of the most recently available data and in- 11 formation on costs) shall apply to a specified 12 breakthrough device in the same manner as 13 such provisions apply to a breakthrough device. 14 The Secretary may use methodologies under ex- 15 isting payment systems established under this 16 title, may provide for appropriate adjustments 17 to such methodologies, or may establish a new 18 payment methodology under this title, to pro- 19 vide for payment for a specified breakthrough 20 device to ensure the payment basis for such 21 payment covers costs of the specified break- 22 through device are covered by such payment. 23 ''(B) R EPORT .\u2014 24 VerDate Nov 24 GENERAL .\u2014With respect to 1 each specified breakthrough device, the 2 Secretary shall submit to Congress a re- 3 port on the coverage of and payment for 4 such specified breakthrough device under 5 this section that includes the following in- 6 formation: 7 ''(I) The manner in which cov- 8 erage is provided and payment is 9 made for the specified breakthrough 10 device, including how such device was 11 classified (such as an item of durable 12 medical equipment or otherwise) and 13 the payment methodology the Sec- 14 retary applied with respect to such de- 15 vice. 16 ''(II) The impact of the avail- 17 ability of the specified breakthrough 18 device to Medicare beneficiaries, in- 19 cluding impacts on the quality of pa- 20 tient care, patient outcomes, and pa- 21 tient experience. 22 ''(III) The impact of the avail- 23 ability of the specified breakthrough 24 VerDate Nov 24 2008 15:17 to Medicare beneficiaries on 1 program expenditures under this title. 2 ''(IV) Such other information as 3 the Secretary determines to be appro- 4 priate. 5 ''(ii) D EADLINE .\u2014 6 ''(I) I N GENERAL .\u2014Except as 7 provided in subclause (II), the Sec- 8 retary shall submit a report required 9 under this subparagraph no later than 10 the end of the transitional period of 11 coverage and payment applicable to 12 such specified breakthrough device. 13 ''(II) E XTENSION TO GENERATE 14 ADDITIONAL DATA .\u2014If the Secretary 15 determines that additional data or evi- 16 dence is required to complete a report 17 required under this subparagraph 18 with respect to a specified break- 19 through device, the deadline under 20 this clause may be extended for an 21 additional two years. 22 ''(C) A DDITIONAL PERIOD OF TRANSI - 23 TIONAL COVERAGE TO DEVELOP ADDITIONAL 24 DATA .\u2014Insofar as the Secretary determines 25 VerDate Nov 24 2008 additional data or evidence is required to 1 complete a report required under subparagraph 2 (B) with respect to a specified breakthrough de- 3 vice, the transitional coverage period of cov- 4 erage and payment for such device shall be ex- 5 tended by the lesser of\u2014 6 ''(i) two years; or 7 ''(ii) the amount of additional time re- 8 quired for the submission of the report 9 with respect to such device. 10 ''(3) C OVERAGE AND PAYMENT AFTER THE 11 TRANSITIONAL PERIOD .\u2014The Secretary may con- 12 tinue to provide for coverage of and payment for a 13 specified breakthrough device after the end of the 14 transitional period of coverage and payment for 15 breakthrough devices through the national coverage 16 determination process if the Secretary determines 17 that the specified breakthrough device\u2014 18 ''(A) improves the quality of care and pa- 19 tient outcomes; 20 ''(B) improves the delivery of care; or 21 ''(C) reduces spending under this title 22 without reducing the quality of care.''. 23 (b) C ONFORMING AMENDMENTS .\u2014 24 VerDate Nov 24 2008 PAYMENT SYS - 1 TEM.\u2014Section 1886(d)(5)(K) of the Social Security 2 Act (42 U.S.C. 1395ww(d)(5)(K)) is amended by 3 adding at the end the following new clause: 4 ''(x) Effective for discharges occurring on 5 or after October 1, 2019, in the case of a new 6 medical service or technology that is a break- 7 through device (as defined in section 8 1899C(a)), the additional payment established 9 for such breakthrough device under this sub- 10 paragraph shall be made for the 4-year period 11 applicable to such breakthrough device under 12 section 1899C(d)(1). In determining the 13 amount of the additional payment for a break- 14 through device under this subparagraph during 15 such 4-year period, the Secretary shall apply 16 section 412.88(b) of title 42, Code of Federal 17 Regulations, as in effect on the date of the en- 18 actment of this clause, except as if the ref- 19 erence in such section to '65 percent' were a 20 reference to '65 percent (or such greater per- 21 cent specified by the Secretary)'.''. 22 (2) O UTPATIENT PROSPECTIVE PAYMENT SYS - 23 TEM.\u2014Section 1833(t)(6)(C) of such Act (42 U.S.C. 24 amended by adding at the end the 1 following new clause: 2 ''(iii) S PECIAL RULE FOR BREAK - 3 THROUGH DEVICES .\u2014Notwithstanding 4 clause (i) or (ii), or any other provision of 5 this paragraph to the contrary, in the case 6 of a breakthrough device (as defined in 7 section 1899C(a)) that is furnished on or 8 after January 1, 2020, payment under this 9 paragraph for such breakthrough device 10 shall be made for the 4-year period appli- 11 cable to such breakthrough device under 12 section 1899C(d)(2). The provisions of this 13 clause shall also apply for purposes of 14 transitional pass-through payment under 15 section 1833(i)(2)(D).''. 16 (c) E FFECTIVE DATE.\u2014This section, and the amend- 17 ments made by this section, shall take effect on the date 18 of the enactment of this Act and, unless otherwise speci-19 fied in this section (or in an amendment made by this sec-20 tion), shall apply to breakthrough devices (as defined in 21 section 1899C(a) of the Social Security Act, as added by 22 subsection (a)), approved or cleared on or after July 1, 23 2019, or, in the case of a specified breakthrough device 24 VerDate Nov 24 2008 15:17 defined in such section as so added), approved or 1 cleared on or after December 1, 2018. 2 SEC. 405. SECRETARY OF HEALTH AND HUMAN SERVICES 3 REPORT ON COVERAGE FOR INNOVATIVE 4 TECHNOLOGIES. 5 Not later than 1 year after the date of the enactment 6 of this Act, the Secretary of Health and Human Services, 7 in collaboration with the Administrator of the Centers for 8 Medicare & Medicaid Services, and following a request for 9 information, shall submit to Congress a report containing 10 a proposal that\u2014 11 (1) specifies, for purposes of payment and cov- 12 erage under title XVIII of the Social Security Act, 13 a definition for digital alternatives to treatment and 14 therapies, including wearables and digital applica- 15 tions and platforms; 16 (2) establishes a standardized process for deter- 17 mining which technologies satisfy the definition pur- 18 suant to paragraph (1); 19 (3) establishes a standardized process for deter- 20 mining coverage under such title of digital alter- 21 natives as defined pursuant to paragraph (1) that 22 are prescribed by a physician; and 23 (4) identifies an innovative system for payment 24 under such title for such alternatives. 25 VerDate Nov 24 2008 15:17 406. SECRETARY OF HEALTH AND HUMAN SERVICES 1 REPORT ON CMS COMPUTER SYSTEMS. 2 Not later than one year after the date of the enact- 3 ment of this Act, the Secretary of Health and Human 4 Services shall submit to Congress a report on the fol-5 lowing: 6 (1) The current state of computer systems of 7 the Centers for Medicare & Medicaid Services, in- 8 cluding an analysis of the capabilities and defi- 9 ciencies of such systems in helping to managing the 10 operations of the programs administered by the Cen- 11 ters for Medicare & Medicaid Services. 12 (2) The cost, taking into account ways to lower 13 or defray costs to the Federal Government, of each 14 of the following: 15 (A) Replacing or updating such systems 16 identified under paragraph (1). 17 (B) Contractors and other third-parties to 18 solve for deficiencies in such system identified 19 under paragraph (1). 20 SEC. 407. PRECISION MEDICINE ANSWERS FOR KIDS 21 TODAY. 22 (a) C ENTERS FOR MEDICARE & M EDICAID SERVICES 23 GUIDANCE ON THE EARLY AND PERIODIC SCREENING , 24 DIAGNOSTIC , AND TREATMENT BENEFIT .\u2014Not later than 25 6 months after the date of enactment of this Act, the Cen-26 VerDate Nov 24 2008 Medicare & Medicaid Services shall issue guidance 1 to States on authority and requirements under the Med-2 icaid program under title XIX of the Social Security Act 3 to provide medically necessary health care that falls within 4 the scope of services specified under section 1905(r) of the 5 Social Security Act (42 U.S.C. 1396d(r)) to a child, re-6 gardless of whether the service is available for adults 7 under the State plan (or waiver of such plan) under such 8 title. The guidance shall\u2014 9 (1) include technical and educational assistance 10 on how to increase the frequency of coverage under 11 the State plan (or waiver) pursuant to paragraphs 12 (4) and (16) of section 1905(a) of such Act (42 13 U.S.C. 1396d(a)) for genetic and genomic testing di- 14 agnostic services, including whole exome sequencing, 15 whole genome sequencing, and gene panels when rec- 16 ommended by a qualified treating provider as a first- 17 or second-tier test for pediatric patients, including 18 those who\u2014 19 (A) have a positive result from a newborn 20 screening program; 21 (B) have one or more neurodevelopmental 22 or congenital anomalies; 23 (C) are experiencing developmental delay 24 or intellectual disability; 25 VerDate Nov 24 2008 having seizures; 1 (E) have been referred or admitted to a 2 pediatric or neonatal intensive care unit for a 3 chronic or undiagnosed disease; 4 (F) have been seen by at least one medical 5 specialist for such chronic or undiagnosed dis- 6 ease; or 7 (G) are suspected by at least one 8 healthcare provider to have a neonatal- or pedi- 9 atric-onset genetic disease; 10 (2) provide education and support to providers 11 to minimize denials of claims for medical assistance 12 under the State plan under title XIX of the Social 13 Security Act resulting from deficient or inadequate 14 paperwork; and 15 (3) ensure that providers and Medicaid-eligible 16 children and the families are aware of the Early and 17 Periodic Screening, Diagnostic and Treatment Ben- 18 efit under title XIX of the Social Security Act and 19 have access to required screenings and necessary 20 treatment services. 21 (b) D EMONSTRATION PROGRAM TO PROVIDE GE- 22 NETIC AND GENOMIC TESTING FOR CERTAIN CHIL- 23 DREN .\u2014 24 VerDate Nov 24 2008 15:17 N GENERAL .\u2014The Secretary of Health and 1 Human Services shall enter into agreements with up 2 to 15 States submitting applications under para- 3 graph (3) for the purpose of conducting, in accord- 4 ance with this subsection, demonstration projects 5 under section 1115 of the Social Security Act (42 6 U.S.C. 1315) in such States during the 3-year pe- 7 riod beginning on the first date of the first fiscal 8 quarter than begins on or after the date of the en- 9 actment of this subsection to test and evaluate the 10 provision of medical assistance under the State plans 11 under title XIX of such Act (or waivers of such 12 plans) to eligible individuals for purposes of pro- 13 viding such individuals with genetic and genomic 14 testing. 15 (2) D EMONSTRATION PROJECT PAYMENT RE - 16 QUIREMENTS .\u2014Under each demonstration project 17 under this section conducted by a State, the fol- 18 lowing shall apply: 19 (A) The State shall provide a health care 20 provider (as defined by the State) with pay- 21 ments for the provision of genetic and genomic 22 testing to any eligible individual. Payments 23 made to a health care provider for such services 24 shall be treated as medical assistance for pur- 25 VerDate Nov 24 2008 of the Social Security 1 Act (42 U.S.C. 1396b(a)), except that the Fed- 2 eral medical assistance percentage applicable to 3 such payments shall be equal to 100 percent. 4 (B) The State shall specify the method- 5 ology the State will use for determining pay- 6 ment for the provision of genetic and genomic 7 testing. Such methodology for determining pay- 8 ment shall be established consistent with section 9 1902(a)(30)(A) of such Act (42 U.S.C. 10 1396a(a)(30)(A)). 11 (3) A PPLICATIONS .\u2014 12 (A) I N GENERAL .\u2014A State desiring to 13 enter into an agreement under paragraph (1) 14 with the Secretary for conducting a demonstra- 15 tion project shall submit to the Secretary an 16 application, in accordance with such form and 17 manner, and application priorities, as specified 18 by the Secretary and that at a minimum in- 19 cludes the following: 20 (i) An explanation of how and the ex- 21 tent to which genetic and genomic testing 22 under the demonstration project of the 23 State will provide information and data on 24 VerDate Nov 24 2008 15:17 such services improve the diagnosis of 1 eligible individuals. 2 (ii) An explanation of how and the ex- 3 tent to which coverage under the State 4 plan (or waiver) pursuant to the dem- 5 onstration project will increase the use of 6 genetic and genomic testing that may in- 7 crease the use of genetic and genomic test- 8 ing that may improve clinical outcomes for 9 eligible individuals. 10 (iii) Procedures for referring any eligi- 11 ble individual who seeks or needs treat- 12 ment in a hospital emergency department 13 to a health care provider who is qualified 14 (as determined by the State) to provide ge- 15 netic and genomic testing. 16 (iv) An explanation of how genetic 17 and genomic testing may improve health 18 outcomes for all populations in the State, 19 including\u2014 20 (I) individuals with a rare genetic 21 disease, including a metabolic disease, 22 neurologic disorders, or hereditary 23 cancer testing in the presence of a 24 VerDate Nov 24 2008 15:17 cancer diag- 1 nosis; and 2 (II) special populations, including 3 infants and children who are critically 4 ill (non-infectious and non-trauma) 5 patients, transplant patients, individ- 6 uals with cardiac disease, and individ- 7 uals with, or who have a family his- 8 tory of, a birth defect or develop- 9 mental disability. 10 (B) P REFERENCES IN CONSIDERING AP - 11 PLICATIONS .\u2014In considering applications sub- 12 mitted under subparagraph (A), the Secretary 13 of Health and Human Services shall give pref- 14 erence to States that can demonstrate under- 15 utilization of genetic and genomic sequencing 16 clinical services (with priority given to States 17 that do not cover whole-genome sequencing or 18 do not cover the majority of genetic and 19 genomic clinical services) in pediatric popu- 20 lations under the State plan under title XIX of 21 the Social Security Act (or waiver of such 22 plan). 23 (4) T ECHNICAL ASSISTANCE .\u2014The Secretary of 24 Health and Human Services shall provide technical 25 VerDate Nov 24 2008 15:17 to assist States in planning and designing 1 the demonstration project for purposes of applying 2 for conducting such project under this section. 3 (5) R EPORTS BY STATES .\u2014Not later than one 4 year after the date on which a State enters into an 5 agreement under paragraph (1) with the Secretary 6 for conducting a demonstration project, the State 7 shall submit a report to the Administrator of the 8 Centers for Medicare & Medicaid Services and the 9 Administrator of the Health Resources and Services 10 Administration on the extent to which genetic and 11 genomic testing improved outcomes and reduced 12 health disparities. Such report shall include informa- 13 tion on the number of patients receiving genetic and 14 genomic testing, the types of services provided, and 15 such other information as the Secretary shall pre- 16 scribe. 17 (6) R EPORTS BY HEALTH CARE PROVIDERS .\u2014 18 As a condition for receiving payment for genetic and 19 genomic testing provided to an eligible individual 20 under a demonstration project conducted by a State 21 under this subsection, a health care provider shall 22 report to the State, in accordance with such require- 23 ments as the Secretary shall specify, on all applica- 24 VerDate Nov 24 2008 determining the quality and effi- 1 cacy of such services. 2 (7) D EFINITIONS .\u2014In this subsection: 3 (A) E LIGIBLE INDIVIDUAL .\u2014The term ''el- 4 igible individual'' means, with respect to a 5 State, an individual who\u2014 6 (i) is eligible for medical assistance 7 under the State plan under title XIX of 8 the Social Security Act (or a waiver of 9 such plan); 10 (ii) is under the age of 21 (or, at the 11 option of the State, under the age of 20, 12 19, or 18 as the State may choose), or in 13 the case of an individual described in sec- 14 tion 1902(a)(10)(A)(i)(IX) of such Act (42 15 U.S.C. 1396a(a)(10)(A)(i)(IX)), under the 16 age of 26; 17 (iii) has been referred or admitted to 18 an intensive care unit, or has been seen by 19 at least one medical specialist, for a sus- 20 pected genetic or undiagnosed disease; or 21 (iv) is suspected by at least one med- 22 ical specialist to have a neonatal-onset or 23 pediatric-onset genetic disease. 24 VerDate Nov 24 1 The term ''genetic and genomic testing'', with 2 respect to an eligible individual\u2014 3 (i) means the determination of a se- 4 quence of deoxyribonucleic acid bases in 5 the genome of such individual, and, if for 6 the sole benefit of the individual, a biologi- 7 cal parent of such individual for the pur- 8 pose of determining whether one or more 9 potentially disease-causing genetic variants 10 are present in the genome of such indi- 11 vidual or such biological parent; and 12 (ii) includes\u2014 13 (I) the sequencing of the whole 14 genome, the whole exome, or a panel 15 of genes; and 16 (II) any analysis, interpretation, 17 and data report derived from such se- 18 quencing. 19 (c) N ATIONAL ACADEMY OF MEDICINE STUDY .\u2014 20 (1) I N GENERAL .\u2014Not later than one year 21 after the date of the enactment of this Act, the Sec- 22 retary of Health and Human Services shall enter 23 into an arrangement with the National Academy of 24 VerDate Nov 24 2008 15:17 which the Academy agrees to 1 study\u2014 2 (A) how genetic and genomic testing may 3 improve preventative care and precision medi- 4 cine; 5 (B) disparities in access to precision 6 diagnostics and associated therapeutics; 7 (C) how genetic and genomic testing may 8 be used to reduce health disparities in 9 marginalized communities; 10 (D) how the Federal Government may help 11 to reduce barriers to genetic and genomic test- 12 ing, including\u2014 13 (i) encouraging the expansion of 14 health insurance coverage of genetic and 15 genomic testing, including diagnostic, pre- 16 dictive, and presymptomatic testing, and 17 genetic and genomic testing (as defined in 18 subsection (b)(7)(B)); 19 (ii) supporting the collection of evi- 20 dence for the clinical utility and appro- 21 priate use of genetic and genomic tests; 22 and 23 (iii) improving access to genetic coun- 24 selors, pathologists, and other relevant pro- 25 24 1 workforce education and training efforts; 2 (E)(i) the extent to which coverage provi- 3 sions in the Medicare and Medicaid programs 4 under titles XVIII and XIX of the Social Secu- 5 U.S.C. 1395 et seq., 1396 et seq.) 6 may restrain the use of genetic and genomic 7 testing that may improve clinical outcomes for 8 beneficiaries; 9 (ii) the extent to which coverage provided 10 pursuant to subsection (a) increased the use of 11 genetic and genomic testing and improved clin- 12 ical outcomes for beneficiaries; and 13 (iii) how the Centers for Medicare & Med- 14 icaid Services may make coverage determina- 15 tions that better suit a precision medicine ap- 16 proach to treatment; and 17 (F) how genetic and genomic testing may 18 improve health outcomes for all pediatric popu- 19 lations in the United States, including\u2014 20 (i) children with a rare disease, in- 21 cluding a metabolic disease, neurologic dis- 22 order, or hereditary cancer testing in the 23 presence of a suspected or confirmed can- 24 cer diagnosis; and 25 VerDate Nov 24 critically ill (non-infectious 2 and non-trauma) patients; 3 (II) transplant patients; 4 (III) individuals with cardiac dis- 5 ease; and 6 (IV) individuals with, or who 7 have a family history of, a birth defect 8 or developmental disability. 9 (2) R EPORT .\u2014 10 (A) I N GENERAL .\u2014The arrangement 11 under paragraph (1) shall provide for the Na- 12 tional Academy of Medicine to submit, not later 13 than 2 years after the date of enactment of this 14 Act, a report on the results of the study under 15 paragraph (1) to\u2014 16 (i) the Secretary of Health and 17 Human Services; 18 (ii) the Committee on Ways and 19 Means and the Committee on Energy and 20 Commerce of the House of Representa- 21 tives; and 22 (iii) the Committee on Finance and 23 the Committee on Health, Education, 24 Labor, and Pensions of the Senate. 25 VerDate Nov 24 2008 15:17 .\u2014The arrangement 1 under paragraph (1) shall provide for the Na- 2 tional Academy of Medicine, in developing the 3 report required by subparagraph (A), to consult 4 with physicians, other health professionals, 5 health educators, health professional organiza- 6 tions, relevant companies, patients, patient or- 7 ganizations, the Health Resources and Services 8 Administration, the National Cancer Institute, 9 the National Institutes of Health, the Agency 10 for Healthcare Research and Quality, and the 11 Centers for Medicare & Medicaid Services. 12 (C) U SE OF INFORMATION .\u2014The National 13 Academy of Medicine shall, to the extent pos- 14 sible, in conducting the study under paragraph 15 (1), utilize information included in the reports 16 submitted pursuant to subsections (f) and (g) 17 of section 2. 18 (d) C ENTERS FOR MEDICARE & M EDICAID SERVICES 19 REPORT ON MEDICAID COVERAGE FOR GENETIC AND 20 GENOMIC TESTING .\u2014Not later than one year after the 21 date of the enactment of this Act, and annually thereafter 22 for the subsequent 3 years, the Centers for Medicare & 23 Medicaid Services shall submit to the Secretary of Health 24 and Human Services, the Committees on Ways and Means 25 VerDate Nov 24 2008 15:17 and Commerce of the House of Represent-1 atives, and the Committees on Finance and Health, Edu-2 cation, Labor, and Pensions of the Senate a report on the 3 extent to which each of the 50 States provide coverage 4 under the State plan under title XIX of the Social Secu-5 rity Act (or waiver of such plan) of genetic and genomic 6 testing (as defined in subsection (b)(7)(B)) (including 7 whole exome, whole genome, gene panels, single gene tests, 8 Chromosomal microarray analysis, Fluorescence in situ 9 hybridization, and other genetic and genomic tests), in-10 cluding information on\u2014 11 (1) how often genetic and genomic diagnostic 12 testing services are covered and reimbursed; 13 (2) the frequency of denials for coverage and 14 the rationale for denying coverage; 15 (3) an analysis of which genetic and genomic 16 diagnostic tests are being approved or denied; 17 (4) how often test genetic counseling is covered 18 pre- and post- genetic and genomic diagnostic test- 19 ing; 20 (5) the turn-around time for prior authorization 21 requests; and 22 (6) any barriers to coverage of genetic and 23 genomic testing services identified. 24 VerDate Nov 24 2008 MEDICARE COVERAGE FOR CONSULTATIONS. 1 (a) I NCLUSION OF CONSULTATIONS AS A MEDICARE 2 BENEFIT .\u2014Section 1861 of the Social Security Act (42 3 U.S.C. 1395x) is amended\u2014 4 (1) in subsection (s)(2)\u2014 5 (A) by striking ''and'' at the end of sub- 6 paragraph (GG); 7 (B) by striking the period at the end of 8 subparagraph (HH) and inserting ''; and''; and 9 (C) by adding at the end the following new 10 subparagraph: 11 ''(II) pharmacogenetic consultations pro- 12 vided by a qualified clinical pharmacist, genetic 13 counselor, or pathologist (as such terms are de- 14 fined in subsection (lll)).''; and 15 (2) by adding at the end the following new sub- 16 section: 17 ''(lll) D term 'pharmacogenetic consultation' means, with re- 20 spect to a genetic or genomic test furnished to an 21 individual, a consultation with respect to such test 22 requested by the physician treating such individual 23 to provide such physician with advice and rec- 24 ommendations regarding the dosage, safety, and effi- 25 cacy of particular drugs, biologicals, and other treat- 24 G ENETIC 'genetic 3 counselor' means an individual who\u2014 4 ''(A) is licensed as a genetic counselor by 5 the State in which the individual furnishes ge- 6 netic counseling services; or 7 ''(B) in the case of an individual practicing 8 in a State that does not license genetic coun- 9 selors, meets such other criteria as the Sec- 10 retary establishes. 11 ''(3) Q UALIFIED CLINICAL PHARMACIST .\u2014The means an indi- 13 vidual\u2014 14 ''(A) with a doctoral degree in pharmacy; 15 ''(B) who is licensed as a pharmacist in 16 the State in which such individual furnishes 17 consultations; 18 ''(C) has appropriate pharmacy specialty 19 certifications or appropriate training, as deter- 20 mined by the Secretary; and 21 ''(D) meets other qualifications as specified 22 by the Secretary.''. 23 VerDate Nov 24 2008 TION .\u2014Section 1832(a)(2) of Social Security Act (42 2 U.S.C. 1395k(a)(2)) is amended\u2014 3 (1) by striking ''and'' at the end of subpara- 4 graph (I); 5 (2) by striking the period at the end of sub- 6 paragraph (J) and inserting ''; and''; and 7 (3) by adding at the end the following new sub- 8 paragraph: 9 ''(K) pharmacogenetic consultations (as 10 defined in subsection (lll)).''. 11 (c) E FFECTIVE DATE.\u2014The amendments made by 12 subsections (a) and (b) shall apply to consultations fur-13 nished during a cost reporting period beginning on or after 14 the date of the enactment of such subsections. 15 SEC. 409. PROHIBITING THE USE OF GEOGRAPHIC TRACK-16 ING FEATURES AND BIOMETRICS WITHIN 17 MEDICAID ELECTRONIC VISIT VERIFICATION 18 SYSTEMS. 19 (a) I NGENERAL .\u2014Section 1903(l)(5)(A) of the So- 20 cial Security Act (42 U.S.C. 1396b(l)(5)(A)) is amended 21 by inserting ''(without the use of geographic tracking or 22 biometrics)'' after ''electronically verified''. 23 amendment made by 1 subsection (a) shall apply with respect to calendar quar-2 ters beginning on or after June 1, 2022. 3 SEC. 410. GENERALLY ACCEPTED STANDARD FOR ELEC-4 TRONIC PRESCRIBING. 5 Section 1860D-4(e) of the Social Security Act (42 6 U.S.C. 1395w-104(e)) is amended by adding at the end 7 the following new paragraph: 8 ''(8) G ENERALLY ACCEPTED STANDARDS .\u2014 9 ''(A) D ESIGNATION OF STANDARDS MAIN - 10 TENANCE ORGANIZATION TO RECOGNIZE GEN - 11 ERALLY ACCEPTED STANDARDS .\u2014Not later 12 than 6 months after the date of the enactment 13 of this paragraph, the Secretary shall designate 14 through rulemaking a standards maintenance 15 organization with the authority to establish, 16 maintain, and modify generally accepted stand- 17 ards for electronic prescribing and electronic 18 prior authorization. The standards maintenance 19 organization named by the Secretary shall be a 20 standard setting body that\u2014 21 ''(i) is a not-for-profit; 22 ''(ii) has established a multi-stake- 23 holder forum for development and approval 24 VerDate Nov 24 2008 15:17 electronic 1 prior authorization standards; 2 ''(iii) is a standards development or- 3 ganization accredited by the American Na- 4 tional Standards Institute; and 5 ''(iv) includes in its membership phar- 6 macies, prescribers, prescription drug 7 plans, health information technology devel- 8 opers, and representatives from the Cen- 9 ters for Medicare & Medicaid Services and 10 the Food and Drug Administration. 11 In providing the standards maintenance organi- 12 zation with the authority to establish, maintain, 13 and modify generally accepted standards, the 14 Secretary shall permit the standards mainte- 15 nance organization to recognize up to two 16 versions of a standard as being generally ac- 17 cepted to facilitate the testing of newer stand- 18 ards and to allow a smooth transition from one 19 standard to another. 20 ''(B) A DOPTION OF GENERALLY ACCEPTED 21 STANDARDS .\u2014Not later than six months after 22 making the designation under paragraph (8), 23 the Secretary shall require prescriptions and 24 other information described in paragraph 25 VerDate Nov 24 2008 15:17 covered Part D drugs prescribed for 1 Part D eligible individuals that are transmitted 2 electronically to be transmitted only in accord- 3 ance with generally accepted standards, as des- 4 ignated by the standards maintenance organiza- 5 tion named by the Secretary under subpara- 6 graph (A), under an electronic prescription 7 drug program that meets the requirements of 8 paragraph (2).''. 9 Subtitle B 10 SEC. 411. MEANINGFUL ACCESS TO FEDERAL HEALTH 11 PLAN CLAIMS DATA. 12 (a) F INDINGS .\u2014Congress finds as follows: 13 (1) Clinician-led clinical data registries serve an 14 important role in promoting, facilitating, and con- 15 ducting medical research and improving quality of 16 healthcare by providing timely and actionable feed- 17 back to practitioners on their performance in rela- 18 tion to other practitioners and best clinical practices. 19 (2) Clinician-led clinical data registries are hin- 20 dered in their ability to promote medical research 21 and quality improvement by their lack of meaningful 22 access to claims data. 23 (3) While the Centers for Medicare and Med- 24 icaid Services has established programs for providing 25 VerDate Nov 24 2008 15:17 claims data, those programs fail to provide 1 clinician-led clinical data registries with meaningful 2 access to such data. 3 (4) Ensuring clinician-led clinical data reg- 4 istries meaningful access to claims data will enable 5 such entities to better track patient outcomes over 6 time, expand their ability to assess the safety and ef- 7 fectiveness of medical treatments, and provide them 8 with the information necessary to assess the cost-ef- 9 fectiveness of therapies. 10 (b) E NSURING MEANINGFUL ACCESS TO CLAIMS 11 DATA.\u2014 12 (1) E STABLISHMENT OF A NEW PROGRAM .\u2014 13 The Secretary shall establish a new program (sepa- 14 rate from any existing data access programs, includ- 15 ing, without limitation, the Centers for Medicare and 16 Medicaid Services Qualified Entity (in this section, 17 referred to as ''QE'') Program (42 U.S.C. 18 1395kk(e), 1395kk-2) (in this section, referred to as 19 the ''Medicare Data Sharing for Performance Meas- 20 urement Program'') and the Research Data Assist- 21 ance Center (in this section, referred to as the 22 ''ResDAC'') process) under which the Secretary 23 shall, at the request of a clinician-led clinical data 24 registry, provide timely, broad, and continuous ac- 25 VerDate Nov 24 2008 15:17 database of claims data to such clinician- 1 led clinical data registry for purposes of research, 2 quality of care measurement and reporting to health 3 care providers, linking such data with clinical data 4 and performing risk-adjusted, scientifically valid 5 analyses and research to support quality improve- 6 ment or patient safety, and other purposes and uses 7 described herein or approved by the Secretary. Ac- 8 cess to a database of claims data pursuant to this 9 subsection shall not be more restrictive than access 10 to data provided under the QE Program or the 11 ResDAC process. 12 (2) S TREAMLINED APPLICATION PROCESS .\u2014 13 (A) I NITIAL AND RECERTIFICATION APPLI - 14 CATION .\u2014Prior to gaining access to a database 15 of claims data under the program established in 16 subsection (a), a clinician-led clinical data reg- 17 istry shall submit to the Secretary an applica- 18 tion demonstrating that it is qualified (as deter- 19 mined by the Secretary) to use claims data. 20 Upon the Secretary's approval of a clinician-led 21 clinical data registry's application described in 22 this subparagraph, the Secretary shall provide 23 access to a database of claims data to such cli- 24 nician-led clinical data registry for a period of 25 VerDate Nov 24 2008 15:17 least 5 years. After the expiration of the time 1 period described in this subparagraph, the clini- 2 cian-led clinical data registry shall reapply to 3 access the database of claims data under the 4 program established in subsection (a). 5 (B) P ROCESS .\u2014The Secretary shall estab- 6 lish a streamlined initial application and recer- 7 tification application process under which the 8 Secretary shall approve or deny the clinician-led 9 clinical data registry's application described in 10 subparagraph (2)(A) within 60 calendar days 11 after receiving the application unless the Sec- 12 retary demonstrates a compelling reason for 13 needing additional time to complete the process. 14 If the clinician-led clinical data registry's appli- 15 cation described in subparagraph (2)(A) is de- 16 nied, the Secretary shall provide the reason(s) 17 for denial. 18 (3) A PPEAL RIGHTS .\u2014 19 (A) O PPORTUNITY TO APPEAL .\u2014The Sec- 20 retary shall develop and maintain a process by 21 which a clinician-led clinical data registry may 22 appeal\u2014 23 (i) the Secretary's decision to deny an 24 application described in paragraph (2); and 25 VerDate Nov 24 2008 failure to approve 1 or deny the clinician-led clinical data reg- 2 istry's application described in paragraph 3 (2) within a reasonable time frame estab- 4 lished by the Secretary. 5 (B) D EADLINE FOR DECISION .\u2014The Sec- 6 retary shall render a decision with respect to an 7 appeal filed by a clinician-led clinical data reg- 8 istry pursuant to subparagraph (A) in a timely 9 manner, not to exceed 60 calendar days after 10 the Secretary receives the clinician-led clinical 11 data registry's request for an appeal. Notice of 12 such decision shall be provided to the clinician- 13 led clinical data registry filing the appeal before 14 the conclusion of such 60-day period. 15 (4) B ROAD AND TIMELY ACCESS TO DATA .\u2014 16 The Secretary shall structure its database of claims 17 data to allow for various data set queries, including, 18 but not limited to, provider-specific claims data, clin- 19 ical specialty-specific claims data, state-specific 20 claims data, and nationwide claims data. The Sec- 21 retary shall promptly make available to a clinician- 22 led clinical data registry access to claims data re- 23 quested by such clinician-led clinical data registry 24 within a reasonable timeframe, not to exceed 30 cal- 25 VerDate Nov 24 2008 the Secretary approves the request 1 from the clinician-led clinical data registry. 2 (c) P ERMISSIBLE USES OF CLAIMS DATA.\u2014Clini- 3 cian-led clinical data registries may\u2014 4 (1) make available to the public reports evalu- 5 ating the performance of providers of services and 6 suppliers using the claims data provided to such cli- 7 nician-led clinical data registry under subsection (a) 8 in combination with registry data; 9 (2) use claims data received under subsection 10 (a) combined with registry data to conduct addi- 11 tional nonpublic analyses and provide or charge an 12 access fee for such analyses to authorized users for 13 nonpublic use; 14 (3) provide or charge an access fee for data sets 15 that link claims data received under subsection (a) 16 with registry data to authorized users for nonpublic 17 use; and 18 (4) provide or charge an access fee for claims 19 data received under subsection (a) to authorized 20 users for nonpublic use. 21 (d) F EES.\u2014 22 (1) C LAIMS DATA PROVIDED TO CLINICIAN -LED 23 CLINICAL DATA REGISTRIES .\u2014Claims data shall be 24 provided to a clinician-led clinical data registry 25 VerDate Nov 24 2008 (a) at a reasonable fee based on 1 the cost of providing such data to the clinician-led 2 clinical data registry. Such fee shall be based at 3 least in part on the number of patients included in 4 the claims data provided to such clinician-led clinical 5 data registry. Any fee collected pursuant to the pre- 6 ceding sentences shall be deposited in the Centers 7 for Medicare and Medicaid Services Program Man- 8 agement Account. 9 (2) A NALYSES AND DATA PROVIDED TO AU - 10 THORIZED USERS .\u2014A clinician-led clinical data reg- 11 istry may charge a reasonable, cost-based fee for 12 providing to authorized users claims data, data sets 13 linking claims data with registry data, or analyses 14 described in subsection (b). 15 (e) P ROTECTION OF INFORMATION .\u2014 16 (1) P RIVACY , SECURITY , AND DISCLOSURE 17 LAWS .\u2014The Secretary shall provide access to a 18 database of claims data pursuant to subsection (a) 19 in accordance with applicable information, privacy, 20 security, and disclosure laws, including, without limi- 21 tation, the Health Insurance Portability and Ac- 22 countability Act of 1996 (Public Law 104-191) as 23 amended by the privacy and security provisions set 24 forth in section 13400 of the Health Information 25 VerDate Nov 24 2008 Economic and Clinical Health Act 1 (Public Law 111-5), the regulations promulgated 2 thereunder codified at parts 160 and 164 of title 45, 3 Code of Federal Regulations, and subparagraphs (A) 4 through (B) of section 105(a)(3) of the Medicare 5 Access and CHIP Reauthorization Act of 2015 (42 6 U.S.C. 1395kk-2(a)(3)). 7 (2) P ROHIBITION ON USING ANALYSES OR DATA 8 FOR MARKETING PURPOSES .\u2014An authorized user 9 shall not use analyses or data provided or sold under 10 paragraphs (2) through (4) of subsection (b) for 11 marketing purposes. 12 (3) N O REDISCLOSURE OF ANALYSES OR 13 DATA .\u2014An authorized user in receipt of an analysis 14 or datum provided or sold under paragraphs (2) 15 through (4) of subsection (b) shall comply with sec- 16 tion 105(a)(5) of Medicare Access and CHIP Reau- 17 thorization Act of 2015 (42 U.S.C. 1395kk-2(a)(5)). 18 (4) O PPORTUNITY FOR PROVIDERS OF SERV - 19 ICES AND SUPPLIERS TO REVIEW .\u2014Prior to a clini- 20 cian-led clinical data registry using, providing, or 21 charging an access fee for claims data, data sets 22 linking claims data with registry data, or analyses 23 described in subsection (b), to the extent that such 24 data, data sets, or analyses would individually iden- 25 VerDate Nov 24 2008 provider of services or supplier who is not 1 being provided or sold such data, data sets, or anal- 2 yses, such clinician-led clinical data registry shall 3 confidentially make available such data, data sets, or 4 analyses to such provider of services or supplier and 5 provide such provider of services or supplier with the 6 opportunity to appeal and correct errors. 7 (f) D ATA USEAGREEMENT .\u2014A clinician-led clinical 8 data registry and an authorized user shall enter into a 9 data use agreement regarding the use or disclosure of any 10 claims data or data sets that link claims data with registry 11 data that the clinician-led clinical data registry is pro-12 viding or charging an access fee to the authorized user 13 under paragraphs (3) through (4) of subsection (b). Such 14 agreement shall include the requirements and prohibitions 15 described in section 105(a)(4) of the Medicare Access and 16 CHIP Reauthorization Act of 2015 (42 U.S.C. 1395kk- 17 2(a)(4)). 18 (g) A SSESSMENT FOR A BREACH .\u2014 19 (1) I N GENERAL .\u2014In the case of a breach of a 20 data use agreement described in subsection (e), the 21 Secretary shall impose an assessment on the clini- 22 cian-led clinical data registry and the authorized 23 user. 24 VerDate Nov 24 2008 15:17 assessment under para- 1 graph (1) shall be in an amount up to $100 for each 2 individual entitled to, or enrolled for, benefits under 3 part A of title XVIII of the Social Security Act or 4 enrolled for benefits under part B of such title for 5 whom the clinician-led clinical data registry provided 6 data on to the authorized user. 7 (3) D EPOSIT OF AMOUNTS COLLECTED .\u2014Any 8 amounts collected pursuant to this subsection shall 9 be deposited in the Federal Supplementary Medical 10 Insurance Trust Fund under section 1841 of the So- 11 cial Security Act (42 U.S.C. 1395t). 12 (h) D ISCOVERY OR ADMISSION AS EVIDENCE .\u2014 13 Claims data released to a clinician-led clinical data reg-14 istry under subsection (a) shall not be subject to discovery 15 or admission as evidence in judicial or administrative pro-16 ceedings without consent of the applicable provider of 17 services or supplier. 18 (i) R EPORT TO CONGRESS .\u2014Not later than 2 years 19 after the date of enactment of this Act, and annually 20 thereafter, the Secretary shall submit to Congress a report 21 on the extent to which clinician-led clinical data registries 22 are afforded meaningful access to claims data. 23 (j) D EFINITIONS .\u2014In this subtitle: 24 ''authorized 1 user'' has the meaning given such term in section 2 105(a)(9)(A) of the Medicare Access and CHIP Re- 3 authorization Act of 2015 (42 U.S.C. 1395kk- 4 2(a)(9)(A)), as well as a government agency or other 5 governmental entity, researchers, entities that seek 6 data for purposes of complying with regulations or 7 other requirements of the Federal Food and Drug 8 Administration, and other entities approved by the 9 Secretary. 10 (2) C LAIMS DATA .\u2014The term ''claims data'' 11 has the meaning given to the term ''data'' in section 12 105(b)(1)(B) of the Medicare Access and CHIP Re- 13 authorization Act of 2015 (42 U.S.C. 1395kk- 14 2(b)(1)(B)). 15 (3) C LINICIAN -LED CLINICAL DATA REG - 16 ISTRY .\u2014The term ''clinician-led clinical data reg- 17 istry'' has the meaning given such term in section 18 4005(b) of the 21st Century Cures Act. 19 (4) N ONPUBLIC USE .\u2014The term ''nonpublic 20 use'' means a use for the purpose of\u2014 21 (A) promoting, facilitating, and conducting 22 medical research, assisting providers of services 23 and suppliers to improve patient safety, and to 24 develop and participate in quality and patient 25 VerDate Nov 24 2008 15:17 devel- oping new models of care; 2 (B) assisting clinician-led clinical data reg- 3 istries in developing and reporting quality meas- 4 ures to health care providers quality measures; 5 (C) educating a government agency or 6 other governmental entity; and 7 (D) supporting clinical trials and other ac- 8 tivities necessary to comply with pre- or post- 9 market approval or adverse event reporting re- 10 quirements or conditions imposed by the Food 11 and Drug Administration, and other purpose 12 approved by the Secretary. 13 (5) P ROVIDER OF SERVICES .\u2014The term ''pro- 14 vider of services'' has the meaning given such term 15 in section 1861(u) of the Social Security Act (42 16 U.S.C. 1395x(u)). 17 (6) S UPPLIER .\u2014The term ''supplier'' has the 18 meaning given such term in section 1861(d) of the 19 Social Security Act (42 U.S.C. 1395x(d)). 20 (k) R EGULATIONS .\u2014Not later than 1 year after the 21 date of the enactment of this Act, the Secretary of Health 22 and Human Services shall promulgate final regulations to 23 implement the provisions of the preceding sections of this 24 subtitle. 25 VerDate Nov 24 2008 15:17 1 SEC. 501. ADVANCED RESEARCH PROJECTS AGENCY FOR 2 HEALTH. 3 (a) E STABLISHMENT .\u2014The Secretary of Health and 4 Human Services, acting through the Director of the Na-5 tional Institutes of Health, shall establish the Advanced 6 Research Projects Agency for Health (to be referred to 7 in this Act as ''ARPA-H'') to transform and improve im-8 portant areas of medicine and health for the wellbeing of 9 all individuals in the United States. 10 (b) G OALS .\u2014 11 (1) I N GENERAL .\u2014The goals of ARPA-H shall 12 be to deliver breakthrough capabilities through tech- 13 nologies, systems, and platforms that\u2014 14 (A) accelerate the discovery and applica- 15 tion of transformational innovations in health 16 and medical product development; and 17 (B) reduce the human and economic cost 18 of disease. 19 (2) M EANS .\u2014ARPA-H may achieve the estab- 20 lished goals under paragraph (1), including by any 21 of the following means: 22 (A) Promoting high-risk, high-reward inno- 23 vation. promoting revolu- 1 tionary advances in biomedical and health re- 2 search that enable new paradigms in health. 3 (C) Accelerating transformational health 4 advances in areas that the relevant industries 5 by themselves are not likely to undertake be- 6 cause of technical, financial, or other uncer- 7 tainty. 8 (D) Prioritizing project investments based 9 on scientific opportunity and uniqueness of fit 10 to ARPA-H strategies and operating practice, 11 together with the prospective impact on disease 12 burden (regardless of disease prevalence), both 13 human and fiscal, including the health care fis- 14 cal liability of the Federal government. 15 (E) Partnering with, and providing fund- 16 ing to, a broad range of institutions, including 17 universities, national laboratories, public sector 18 organizations, private companies, nonprofit or- 19 ganizations, and foreign institutions. 20 (c) D IRECTOR .\u2014 21 (1) I N GENERAL .\u2014 ARPA-H shall be headed 22 by a Director, who shall be appointed by and serve 23 at the pleasure of the President (referred to in this 24 section as the ''Director of ARPA-H''). 25 VerDate Nov 24 Director of ARPA-H 1 shall\u2014 2 (A) be an individual who, by reason of pro- 3 fessional background and experience, is quali- 4 fied to advise the Secretary on, and manage re- 5 search programs addressing, matters pertaining 6 to long-term and high-risk barriers to the devel- 7 opment of health innovation; 8 (B) have authority to execute contracts de- 9 veloped by in-house program managers who se- 10 lect external performers, and maintain, enhance 11 or terminate projects based on performance 12 against explicit milestones; and 13 (C) have a time-limited appointment of 5 14 years with the opportunity, at the discretion of 15 the President, of one extension. 16 (3) D UTIES .\u2014The duties of the Director of 17 ARPA-H shall be to\u2014 18 (A) set national research priorities to ad- 19 vance the mission of the agency as informed by 20 a multi-sectoral board of advisors; 21 (B) approve all new programs within 22 ARPA-H; 23 (C) have final funding authority to initiate 24 and terminate program funding; 25 VerDate Nov 24 2008 for funding and as- 1 sessing the success of programs through the es- 2 tablishment of technical milestones; 3 (E) appoint the personnel necessary, con- 4 sistent with subsection (d), to successfully exe- 5 cute the goals of ARPA-H; and 6 (F) designate employees to serve as pro- 7 gram managers to carry out the duties de- 8 scribed in subsection (e) for each of the pro- 9 grams established pursuant to the responsibil- 10 ities established for ARPA-H. 11 (4) A UTHORITY .\u2014The Director of ARPA-H is 12 authorized to\u2014 13 (A) acquire (by purchase, lease, condemna- 14 tion, or otherwise), construct, improve, repair, 15 operate, and maintain such real and personal 16 property as are necessary to carry out this sec- 17 tion; and 18 (B) lease an interest in property for not 19 more than 20 years, notwithstanding section 20 1341(a)(1) of title 31, United States Code. 21 (d) P ERSONNEL MANAGEMENT AUTHORITY .\u2014 22 (1) S PECIAL PERSONNEL MANAGEMENT AU - 23 THORITY .\u2014The Director of ARPA-H may\u2014 appointments to positions of ad- 1 ministration or management of ARPA-H with- 2 out regard to any provision in title 5, United 3 States Code, governing appointments under the 4 civil service laws and fix the compensation of 5 such positions at a rate not to exceed the 6 amount of annual compensation (excluding ex- 7 penses) specified in section 102 of title 3, 8 United States Code, notwithstanding section 9 202 of Department of Health and Human Serv- 10 ices Appropriations Act, 1993 (Public Law 11 102-394); 12 (B) hire personnel under section 207(f) of 13 the Public Health Service Act (42 U.S.C. 14 209(f)) and establish governing criteria to re- 15 cruit, appoint, and compensate personnel under 16 this section notwithstanding section 202 of De- 17 partment of Health and Human Services Ap- 18 propriations Act, 1993 (Public Law 102-394) 19 or any provision of title 5, United States Code, 20 governing the rates of pay or classification of 21 employees in the Executive branch; 22 (C) make additional appointments of sci- 23 entific, medical, and professional personnel 24 under this section without regard to any provi- 25 VerDate Nov 24 2008 title 5, United States Code, governing 1 appointments under the civil service laws and 2 fix the compensation of such personnel at a rate 3 to be determined by the Director, up to the 4 amount of annual compensation (excluding ex- 5 penses) specified in section 102 of title 3, 6 United States Code, notwithstanding section 7 202 of Department of Health and Human Serv- 8 ices Appropriations Act, 1993 (Public Law 9 102-394) or any provision of title 5, United 10 States Code, governing the rates of pay or clas- 11 sification of employees in the Executive branch; 12 and 13 (D) recruit and retain a diverse workforce, 14 including individuals underrepresented in 15 science and medicine and racial and ethnic mi- 16 norities. 17 (2) A DDITIONAL STAFF .\u2014The Director of 18 ARPA-H may use all authorities in existence on the 19 date of enactment of this Act that are provided to 20 the Secretary to hire administrative, financial, infor- 21 mation technology staff, and any other staff the Di- 22 rector of ARPA-H determines are necessary to 23 carry out this section. 24 (3) L IMITATION ON TERM .\u2014 25 VerDate Nov 24 2008 15:17 GENERAL .\u2014Except as provided in 1 subparagraph (B), the service of an employee 2 under an appointment under paragraph (1)(A) 3 in the position of a program manager may not 4 exceed 3 years. 5 (B) E XTENSION .\u2014The Director of ARPA- 6 H may, in the case of a particular employee, ex- 7 tend the period to which service is limited under 8 subparagraph (A) by up to 3 years if the Direc- 9 tor determines that such action is necessary to 10 promote the efficiency of ARPA-H. 11 (4) L IMITATION ON ADDITIONAL PAYMENTS .\u2014 12 The total amount of the additional payments paid to 13 an employee under paragraph (1)(C) for any 12- 14 month period may not exceed the least of the fol- 15 lowing amounts: 16 (A) $25,000. 17 (B) The amount equal to 25 percent of the 18 employee's annual rate of basic pay. 19 (C) The amount of the limitation that is 20 applicable for a calendar year under section 21 5307(a)(1) of title 5, United States Code. 22 (e) P ROGRAM MANAGERS .\u2014An employee designated 23 as a program manager pursuant to subsection (c)(3)(F) 24 shall\u2014 25 define the research and development goals 1 and milestones of the program involved, in line with 2 guidance from the Director; 3 (2) track progress and course-correct projects 4 when needed; 5 (3) recommend, as necessary, the restructuring 6 or termination of projects supported by ARPA-H; 7 and 8 (4) select, on the basis of merit and need, each 9 of the projects to be supported under the program 10 involved after considering\u2014 11 (A) the novelty and scientific and technical 12 merit of the proposed projects; 13 (B) the demonstrated capabilities of the 14 applicants to successfully carry out the pro- 15 posed project; 16 (C) the consideration by the applicant of 17 future commercial applications of the project; 18 or 19 (D) the unmet need within patient popu- 20 lations. 21 (f) R EPORTS .\u2014 22 (1) S TRATEGIC VISION .\u2014Not later than 180 23 days after the date of the enactment of this Act, the 24 Director of ARPA-H shall provide to the Committee 25 VerDate Nov 24 2008 15:17 Energy and Commerce and the Committee on 1 Appropriations of the House of Representatives and 2 the Committee on Health, Education, Labor and 3 Pensions and the Committee on Appropriations of 4 the Senate a report describing the strategic vision 5 that ARPA-H will use to guide the choices of 6 ARPA-H for future health investments over the fol- 7 lowing 3 fiscal years beginning on or after the date 8 of the enactment of this Act. 9 (2) A NNUAL BUDGET REQUEST .\u2014As part of 10 the annual budget request submitted for each fiscal 11 year, the Director of ARPA-H shall provide to the 12 congressional committees specified in paragraph (1) 13 a report describing\u2014 14 (A) projects supported by ARPA-H during 15 the previous fiscal year, including\u2014 16 (i) the transition of projects' outcomes 17 to clinical practice; 18 (ii) the impact on clinical outcome; 19 and 20 (iii) the creation of biomedical capa- 21 bilities; and 22 (B) successes and barriers to scientific 23 interchanges; 24 (C) rapid knowledge transfer; 25 VerDate Nov 24 optimization; and 1 (E) heightened investment impact among 2 collaborators. 3 (3) R EPORT ON COOPERATIVE AGREEMENTS 4 AND OTHER TRANSACTION .\u2014Not later than 90 days 5 after the end of each fiscal year, the Director of 6 ARPA-H shall submit to the congressional commit- 7 tees specified in paragraph (1) a report on all coop- 8 erative agreements and other transactions (other 9 than contracts and grants) entered into under this 10 subsection during such fiscal year. The report shall 11 contain, with respect to such cooperative agreement 12 and transaction, the following: 13 (A) A general description of the coopera- 14 tive agreement or other transaction (as the case 15 may be), including the innovations for which 16 advanced research is provided for under such 17 agreement or transaction. 18 (B) The potential clinical and, if any, com- 19 mercial utility of such innovations. 20 (C) The reasons for not using a contract 21 or grant to provide support for such advanced 22 research. 23 (D) The amount of the payments, if any, 24 referred to in subsection (i)(2) that were re- 25 VerDate Nov 24 the Federal Government in connection 1 with such cooperative agreement or other trans- 2 action during the fiscal year covered by the re- 3 port. 4 (E) The amount of the payments reported 5 under subparagraph (D), if any, that were cred- 6 ited to the account established under subsection 7 (i)(7). 8 (g) C OORDINATION AND NONDUPLICATION .\u2014 9 (1) I N GENERAL .\u2014The Director of ARPA-H 10 shall ensure effective, early, and frequent coordina- 11 tion between ARPA-H and the heads of the re- 12 search, public health, and regulatory agencies of the 13 Department of Health and Human Services, includ- 14 ing\u2014 15 (A) the Director of the National Institutes 16 of Health; 17 (B) the Commissioner of Food and Drugs; 18 (C) the Administrator of the Centers for 19 Medicare and Medicaid Services; 20 (D) the Director of the Centers for Disease 21 Control and Prevention; and 22 (E) the Assistant Secretary for Prepared- 23 ness and Response. 24 VerDate Nov 24 2008 The Director of the National Science 1 Foundation. 2 (G) The Director of the Office of Science 3 of the Department of Energy. 4 (2) C OORDINATION .\u2014The Director shall also 5 coordinate among the full set of advanced research 6 project agencies including\u2014 7 (A) the Defense Advanced Research 8 Project Agency; 9 (B) the Advanced Research Project Agen- 10 cy-Energy; and 11 (C) others as they may be established. 12 (h) A DVICE .\u2014 13 (1) I N GENERAL .\u2014The Director of ARPA-H 14 may seek advice on any aspect of ARPA-H from\u2014 15 (A) any advisory committee that, as of the 16 date of the enactment of this Act, is providing 17 advice to the Secretary of Health and Human 18 Services (or any head of a research, public 19 health, or regulatory agency of the Department 20 of Health and Human Services); and 21 (B) an advisory committee established on 22 or after such date of enactment to support the 23 programs of ARPA-H and to provide advice 24 and assistance on\u2014 25 VerDate Nov 24 2008 tasks; or 1 (ii) overall direction of ARPA-H. 2 (2) A DDITIONAL SOURCES .\u2014In addition to the 3 advisory committees specified in paragraph (1), the 4 Director of ARPA-H may seek advice and review 5 from\u2014 6 (A) the President's Committee of Advisors 7 on Science and Technology; 8 (B) any professional or scientific organiza- 9 tion with expertise in specific processes or tech- 10 nologies under development by ARPA-H; and 11 (C) representatives of patient communities. 12 (i) C OOPERATIVE AGREEMENTS AND OTHER TRANS - 13 ACTIONS .\u2014 14 (1) I N GENERAL .\u2014The Director of ARPA-H, 15 in carrying out advanced research projects through 16 ARPA-H, may enter into grants, contracts, coopera- 17 tive agreements, cash prizes, and other transactions 18 (as defined in section 319L(a) of the Public Health 19 Service Act (42 U.S.C. 247d-7e(a))) with any per- 20 son, any agency or instrumentality of the United 21 States, any unit of State or local government, and 22 any other entity institutions, including universities, 23 national laboratories, public sector organizations, 24 VerDate Nov 24 2008 15:17 nonprofit organizations, and for- 1 eign institutions. 2 (2) T ERMS .\u2014 3 (A) R EQUIRED PROVISIONS .\u2014The Director 4 of ARPA-H shall ensure that, in entering into 5 cooperative agreements and other transactions 6 under paragraph (1)\u2014 7 (i) to the extent the Director of 8 ARPA-H determines practicable, the Fed- 9 eral funds provided under the cooperative 10 agreement or other transaction do not ex- 11 ceed the total amount provided by other 12 parties to the cooperative agreement or 13 other transaction; and 14 (ii) the authority under paragraph (1) 15 is used only when the use of standard con- 16 tracts or grants is not feasible or appro- 17 priate. 18 (B) O PTIONAL PROVISION .\u2014Cooperative 19 agreements and other transactions entered into 20 by the Director of ARPA-H under paragraph 21 (1) may include a clause that requires a person 22 or other entity to make payments to ARPA-H 23 (or any other department or agency of the Fed- 24 eral Government) as a condition for receiving 25 VerDate Nov 24 2008 15:17 under the agreement or other trans- 1 action. 2 (3) D UPLICATIVE RESEARCH .\u2014The Director of 3 ARPA-H shall ensure that to the maximum extent 4 practicable, a cooperative agreement or other trans- 5 action under this section does not provide for re- 6 search that duplicates research being conducted 7 under existing programs carried out by the Depart- 8 ment of Health and Human Services, the Depart- 9 ment of Defense, or other Federal Government enti- 10 ties. 11 (4) A MOUNT OF PAYMENTS .\u2014The amount of 12 any payment received by the Federal Government 13 pursuant to a requirement imposed under paragraph 14 (1) may be credited, to the extent authorized by the 15 Director of ARPA-H, to the account established 16 under paragraph (7). Amounts so credited shall be 17 merged with other funds in the account and shall be 18 available for the same purposes and the same period 19 for which other funds in such account are available. 20 (5) M ULTI -YEAR CONTRACTS .\u2014 21 (A) I N GENERAL .\u2014The Director of 22 ARPA-H may enter into a multi-year contract 23 if\u2014 24 Nov 24 funds are available and obligated 1 for the contract for the full period of the 2 contract, or for the first fiscal year in 3 which the contract is in effect, and for the 4 estimated costs associated with a necessary 5 termination of the contract; 6 (ii) the Director determines that a 7 multiyear contract will serve the best inter- 8 ests of the Federal Government in carrying 9 out this section; and 10 (iii) the contract includes a provision 11 that the contract shall be terminated if 12 funds are not made available for the con- 13 tinuation of the contract in a fiscal year 14 covered by the contract. 15 (B) T ERMINATION COSTS .\u2014A provision re- 16 ferred to in subparagraph (A)(iii) shall provide 17 that funds available for paying termination 18 costs shall remain available for that purpose 19 until the costs associated with termination of 20 the contract are paid. 21 (6) A PPLICATION OF OTHER PROVISIONS .\u2014The 22 authority provided under paragraph (1) may be ex- 23 ercised without regard to section 3324 of title 31, 24 United States Code. 25 VerDate Nov 24 2008 15:17 .\u2014There is hereby established on 1 the books of the Treasury an account for support of 2 advanced research projects provided for in coopera- 3 tive agreements and other transactions entered into 4 under paragraph (1). Funds in such account shall be 5 available for the payment of such support. 6 (8) P RIZE COMPETITIONS .\u2014The Director of 7 ARPA-H may carry out prize competitions in ac- 8 cordance with section 24 of the Stevenson-Wydler 9 Technology Innovation Act of 1980 (15 U.S.C. 10 3719)) in support of the goals specified in sub- 11 section (b). 12 (9) N ONAPPLICABILITY OF CERTAIN PROVI - 13 SIONS .\u2014Research funded pursuant to this section 14 shall not be subject to\u2014 15 (A) advisory council approval under section 16 405(b)(2) of the Public Health Service Act (42 17 U.S.C. 284(b)(2)); 18 (B) advisory council review under section 19 406(a)(3)(A)(ii) of such Act (42 U.S.C. 20 284a(a)(3)(A)(ii)); or 21 (C) the peer review requirements under 22 section 492 of such Act (42 U.S.C. 284(b)(2), 23 289a). 24 (j) C ONFIDENTIALITY .\u2014 24 N GENERAL .\u2014The information specified in 1 paragraph (2) shall be exempt from disclosure under 2 section 552 of title 5, United States Code (com- 3 monly referred to as the Freedom of Information 4 Act). 5 (2) I NFORMATION .\u2014The information specified 6 in this paragraph is information collected by ARPA- 7 H from recipients of financial assistance awards, in- 8 cluding the following: 9 (A) Plans for commercialization of tech- 10 nologies developed under the award, including 11 business plans, technology-to-market plans, 12 market studies, and cost and performance mod- 13 els. 14 (B) Investments provided to an awardee 15 from third parties (such as venture capital 16 firms, hedge funds, and private equity firms), 17 including the amounts and the percentage of 18 ownership of the awardee provided in return for 19 the investments. 20 (k) E XPEDITING BREAKTHROUGHS THROUGH CO- 21 OPERATION WITHFOOD AND DRUG ADMINISTRATION .\u2014 22 (1) I N GENERAL .\u2014The Secretary of Health and 23 Human Services, acting through the Commissioner 24 of Food and Drugs and in consultation with the Di- 25 VerDate Nov 24 2008 15:17 may take actions to facilitate 1 transformation of biomedical breakthroughs into 2 tangible solutions for patients and to expedite devel- 3 opment of medical products, including through any 4 of the following means: 5 (A) Helping to ensure that medical prod- 6 uct development programs, in as efficient a 7 manner as possible, gather the nonclinical and 8 clinical data necessary to advancing the devel- 9 opment of such products and to obtaining their 10 approval, licensure, or clearance, as applicable, 11 by the Food and Drug Administration under 12 sections 505, 510(k), and 515 of such Act (21 13 U.S.C. 355, 360(k), 360) and section 351 of 14 the Public Health Service Act (42 U.S.C. 262). 15 (B) Expediting review of investigational 16 new drug applications under section 505(i) of 17 the Federal Food, Drug, and Cosmetic Act (21 18 U.S.C. 355(i)), review of investigational device 19 exemptions under section 520(g) of such Act 20 (21 U.S.C. 360j(g)), and review of applications 21 for approval, licensure, and clearance of medical 22 products under sections 505, 510(k), and 515 23 of such Act (21 U.S.C. 355, 360(k), 360) and 24 VerDate Nov 24 of the Public Health Service Act 1 (42 U.S.C. 262). 2 (C) Meeting at appropriate intervals with 3 the Director of ARPA-H and any other appro- 4 priate medical product development partners, 5 such as the Director of the Biomedical Ad- 6 vanced Research and Development Authority to 7 discuss the development status of medical prod- 8 ucts and projects that are the highest priorities 9 to ARPA-H, unless the Director of ARPA-H 10 and the Commissioner of Food and Drugs de- 11 termine that any such meetings are not nec- 12 essary. 13 (2) R ELATION TO OTHERWISE AUTHORIZED AC - 14 TIVITIES OF THE FDA .\u2014The authority specified in 15 paragraph (1) shall not be construed as limiting the 16 authority of the Secretary of Health and Human 17 Services, acting through the Commissioner of Food 18 and Drugs with respect to the review and approval, 19 clearance, authorization for emergency use, or licen- 20 sure of a medical product under the Federal Food, 21 Drug and Cosmetic Act (21 U.S.C. 321 et seq.) or 22 section 351 of the Public Health Service Act (42 23 U.S.C. 262). 24 VerDate Nov 24 2008 .\u2014Utilizing interagency 1 agreements or other appropriate resource allocation 2 mechanisms available, the Director of ARPA-H, 3 using funds made available to ARPA-H, shall reim- 4 burse the Food and Drug Administration for ex- 5 penditures made by the Food and Drug Administra- 6 tion for activities carried out under this section that 7 have been identified by the Commissioner of Food 8 and Drugs and the Director of ARPA-H as being 9 carried out by the Food and Drug Administration. 10 (4) M EDICAL PRODUCT DEFINED .\u2014In this sec- 11 tion, the term ''medical product'' means a drug (as 12 defined in section 201 of the Federal Food, Drug, 13 and Cosmetic Act (21 U.S.C. 321)), a device (as de- 14 fined in such section 201), or a biological product 15 (as defined in section 351 of the Public Health Serv- 16 ice Act (42 U.S.C. 262)). 17 (l) A UTHORIZATION OF APPROPRIATIONS AND BY- 18 PASS BUDGET AUTHORITY .\u2014 19 (1) A UTHORIZATION OF APPROPRIATIONS .\u2014 20 There is authorized to be appropriated to carry out 21 this section $6,500,000,000 for fiscal year 2022, to 22 remain available until expended. 23 (2) B YPASS BUDGET AUTHORITY .\u2014The budget 24 of ARPA-H shall be a separate line item in the an- 25 VerDate Nov 24 2008 15:17 submitted by the President to 1 the Congress. ARPA-H shall have the authority to 2 submit its annual budget request directly to Con- 3 gress concurrently with its submission to the Office 4 of Management and Budget. 5 SEC. 502. RESEARCH INVESTMENT TO SPARK THE ECON-6 OMY. 7 (a) A UTHORITY .\u2014 8 (1) I N GENERAL .\u2014Each officer specified in 9 paragraph (2) may exercise the authorities described 10 in paragraph (3). 11 (2) O FFICERS .\u2014The officers specified in this 12 paragraph are as follows: 13 (A) The Secretary of Commerce, acting 14 through the Administrator of the National Oce- 15 anic and Atmospheric Administration and the 16 Director of the National Institute of Standards 17 and Technology. 18 (B) The Secretary of Agriculture. 19 (C) The Secretary of Defense. 20 (D) The Secretary of Education. 21 (E) The Secretary of Energy, acting for 22 the Department of Energy (with respect to En- 23 ergy Efficiency and Renewable Energy, Nuclear 24 Energy, and Fossil Research and Development) 25 VerDate Nov 24 2008 15:17 the Office of Science, the Ad- 1 vanced Research Projects Agency-Energy 2 (ARPA-E), and the Office of Electricity. 3 (F) The Secretary of the Interior, acting 4 through the Director of the United States Geo- 5 logical Survey. 6 (G) The Secretary of Health and Human 7 Services, acting through the Director of the Na- 8 tional Institutes of Health. 9 (H) The Secretary of Transportation. 10 (I) The Administrator of the National Aer- 11 onautics and Space Administration. 12 (J) The Administrator of the Environ- 13 mental Protection Agency. 14 (K) The Director of the National Science 15 Foundation. 16 (3) A UTHORITIES .\u2014The officers specified in 17 paragraph (2) may\u2014 18 (A) provide supplemental funding to ex- 19 tend the duration of an award disrupted be- 20 cause of the COVID-19 public health emer- 21 gency to a research institution, Research Lab- 22 oratory, or individual that was awarded before 23 the date of the enactment of this Act, or to ex- 24 VerDate Nov 24 2008 15:17 of such an award, in order 1 to\u2014 2 (i) enable a postsecondary student or 3 post-doctoral researcher to complete work; 4 (ii) enable research scientists, tech- 5 nical staff, research associates, and prin- 6 cipal investigators to complete work; 7 (iii) extend the training of a postsec- 8 ondary student, or the employment of a 9 post-doctoral researcher, on an ongoing re- 10 search project for up to 2 years because of 11 the disruption of the job market; 12 (iv) create research opportunities for 13 up to 2 years for graduate students and 14 post-doctoral researchers; 15 (v) replace, refurbish, or otherwise 16 make usable laboratory animals, reagents, 17 equipment, or other items required for re- 18 search; 19 (vi) facilitate other research (including 20 field work), training, and ongoing con- 21 struction activities, including at institu- 22 tions that are disproportionately affected 23 by the COVID-19 public health emergency 24 VerDate Nov 24 2008 15:17 and 1 2-year institutions of higher education); 2 (vii) enable experimental field cam- 3 paigns and maintenance of field infrastruc- 4 ture, including through replacement of dis- 5 rupted experimental data to enable comple- 6 tion of impacted research; and 7 (viii) support training in online course 8 delivery and virtual research experiences 9 that will improve quality and access needed 10 to continue undergraduate, graduate, and 11 post-doctoral training; 12 (B) issue awards to research institutions, 13 Research Laboratories, or other individuals to 14 conduct research on the effects of the COVID- 15 19 and future potential pandemics, on the ef- 16 fects and effectiveness of responses to such dis- 17 eases, and on improving the prediction of the 18 possible courses of such pandemics; and 19 (C) provide flexibility on an award for 20 funds made available to an agency, by any prior 21 or subsequent Act, by modifying the terms and 22 conditions of the award with a research institu- 23 tion, Research Laboratory, or individual due to 24 VerDate Nov 24 2008 15:17 closures or other limitations during the 1 COVID-19 public health emergency. 2 (4) M ODIFICATIONS .\u2014The modifications au- 3 thorized by paragraph (3)(C) include\u2014 4 (A) the provision of supplemental funding 5 to extend the duration of the award concerned; 6 or 7 (B) flexibility on the allowable expenses 8 under such award. 9 (b) P ROCEDURES .\u2014The officers specified in sub- 10 section (a)(2) shall each establish procedures to carry out 11 subsection (a). 12 (c) E XPEDITED AWARDS .\u2014Awards under subsection 13 (a) shall be issued as expeditiously as possible. 14 (d) A UTHORIZATIONS OF APPROPRIATIONS .\u2014 15 (1) D EPARTMENT OF COMMERCE .\u2014There is au- 16 thorized to be appropriated for fiscal year 2021 for 17 the Department of Commerce, $450,000,000 to 18 carry out subsection (a), of which\u2014 19 (A) $300,000,000 shall be for use by the 20 National Oceanic and Atmospheric Administra- 21 tion; and 22 (B) $150,000,000 shall be for use by the 23 National Institute of Standards and Tech- 24 nology. 25 VerDate Nov 24 OF AGRICULTURE .\u2014There is 1 authorized to be appropriated for fiscal year 2021 2 for the Department of Agriculture, $380,000,000 to 3 carry out subsection (a). 4 (3) D EPARTMENT OF DEFENSE .\u2014There is au- 5 thorized to be appropriated for fiscal year 2021 for 6 the Department of Defense, $3,000,000,000 to carry 7 out subsection (a). 8 (4) D EPARTMENT OF EDUCATION .\u2014There is 9 authorized to be appropriated for fiscal year 2021 10 for the Department of Education, $200,000,000 to 11 carry out subsection (a), which shall be for use by 12 the Institute for Education Sciences. 13 (5) D EPARTMENT OF ENERGY .\u2014There is au- 14 thorized to be appropriated for fiscal year 2021 for 15 the Department of Energy, $5,000,000,000 to carry 16 out subsection (a), of which\u2014 17 (A) not less than $3,000,000,000 shall be 18 for use by the Office of Science; 19 (B) not less than $900,000,000 shall be 20 for Energy Efficiency and Renewable Energy; 21 (C) not less than $450,000,000 shall be 22 for Nuclear Energy; 23 (D) not less than $300,000,000 shall be 24 for Fossil Research and Development; 25 VerDate Nov 24 2008 less than $150,000,000 shall be 1 for use by the Advanced Research Projects 2 Agency-Energy; and 3 (F) not less than $100,000,000 shall be 4 for use by the Office of Electricity. 5 (6) D EPARTMENT OF THE INTERIOR .\u2014There is 6 authorized to be appropriated for fiscal year 2021 7 for the Department of the Interior, $300,000,000 to 8 carry out subsection (a), which shall be for use by 9 the United States Geological Survey. 10 (7) D EPARTMENT OF HEALTH AND HUMAN 11 SERVICES .\u2014There is authorized to be appropriated 12 for fiscal year 2021 for the Department of Health 13 and Human Services, $10,000,000,000 to carry out 14 subsection (a), which shall be for use by the Na- 15 tional Institutes of Health. 16 (8) D EPARTMENT OF TRANSPORTATION .\u2014 17 There is authorized to be appropriated for fiscal 18 year 2021 for the Department of Transportation, 19 $300,000,000 to carry out subsection (a), of which 20 not less than $130,000,000 shall be for use by the 21 Federal Aviation Administration. 22 (9) N ATIONAL AERONAUTICS AND SPACE AD - 23 MINISTRATION .\u2014There is authorized to be appro- 24 priated for fiscal year 2021 for the National Aero- 25 Nov 24 $2,000,000,000 to carry out subsection (a). 2 (10) E NVIRONMENTAL PROTECTION AGENCY .\u2014 3 There is authorized to be appropriated for fiscal 4 year 2021 for the Environmental Protection Agency, 5 $200,000,000 to carry out subsection (a). 6 (11) N ATIONAL SCIENCE FOUNDATION .\u2014There 7 is authorized to be appropriated for fiscal year 2021 8 for the National Science Foundation, 9 $3,000,000,000 to carry out subsection (a). 10 (12) A VAILABILITY OF FUNDS FOR ADMINIS - 11 TRATION .\u2014 12 (A) I N GENERAL .\u2014Amounts authorized to 13 be appropriated by this subsection may be used 14 for the payment of indirect costs of Federal 15 awards under subsection (a), up to the limit 16 otherwise allowable by law and subject to the 17 requirements of part 200 of title 2, Code of 18 Federal Regulations. 19 (B) L IMITATION .\u2014Not more than 5 per- 20 cent of each of the amounts appropriated pur- 21 suant to this subsection may be used for admin- 22 istration of awards under subsection (a). 23 (13) D URATION OF AVAILABILITY .\u2014Amounts 24 authorized to be appropriated by this subsection 25 VerDate Nov 24 2008 available for the purposes described in this 1 subsection through fiscal year 2021. 2 (e) D EFINITIONS .\u2014In this section: 3 (1) A WARD .\u2014The term ''award'' includes a 4 grant, cooperative agreement, or other financial as- 5 sistance. 6 (2) COVID-19 PUBLIC HEALTH EMERGENCY .\u2014 7 The term ''COVID-19 public health emergency'' 8 means the public health emergency declared by the 9 Secretary of Health and Human Services under sec- 10 tion 319 of the Public Health Service Act (42 11 U.S.C. 247d) on January 31, 2020, with respect to 12 coronavirus disease 2019 (COVID-19). 13 (3) R ESEARCH INSTITUTION .\u2014The term ''re- 14 search institution'' means the following: 15 (A) An institution of higher education (as 16 defined in section 101(a) of the Higher Edu- 17 cation Act of 1965 (20 U.S.C. 1001(a))). 18 (B) A Tribal College or University (as de- 19 fined in section 316 of the Higher Education 20 Act of 1965 (20 U.S.C. 1059c)). 21 (C) A nonprofit entity that conducts feder- 22 ally funded research. 23 (4) R ESEARCH LABORATORY .\u2014The term ''Re- 24 search Laboratory'' means the A National Laboratory (as defined in 1 section 2 of the Energy Policy Act of 2005 (42 2 U.S.C. 15801)). 3 (B) A Federally Funded Research and De- 4 velopment Center for purposes of section 5 3.5.017 of title 48, Code of Federal Regula- 6 tions. 7 SEC. 503. RESEARCH POLICY BOARD REAUTHORIZATION. 8 (a) E XTENSION OF SUNSET .\u2014Section 2034(f)(6) of 9 the 21st Century Cures Act (42 U.S.C. 3501 note) is 10 amended by striking ''September 30, 2021'' and inserting 11 ''September 30, 2026''. 12 (b) P ARTICIPATION BY DIRECTOR OF NIH.\u2014 13 (1) I NCLUSION AS MEMBER .\u2014Section 14 2034(f)(2)(A) of the 21st Century Cures Act (42 15 U.S.C. 3501 note) is amended\u2014 16 (A) by redesignating clause (v) as clause 17 (vi); 18 (B) by inserting after clause (iv) the fol- 19 lowing: 20 ''(iv) The Director of the National In- 21 stitutes of Health.''. 22 (2) L IMITATIONS RELATING TO INDIRECT 23 COSTS .\u2014Section 2034(f)(2) of the 21st Century 24 VerDate Nov 24 U.S.C. 3501 note) is amended by 1 adding at the end the following: 2 ''(C) L IMITATIONS RELATING TO INDIRECT 3 COSTS .\u2014Notwithstanding any other provision 4 of law, the Director of the National Institutes 5 of Health may participate in the activities of 6 the Board, including the formulation of rec- 7 ommendations, without regard to limitations re- 8 lating to indirect costs in part 75 of title 45, 9 Code of Federal Regulations (or any successor 10 regulations).''. 11 VerDate Nov 24 2008 "}